Document:

Exhibit
10.1

 

Execution Copy

 

EMPLOYMENT
AGREEMENT

 

This
EMPLOYMENT AGREEMENT (this “Agreement”) is entered into and effective as of September 28, 2020 (the
“Effective Date”), between H-Cyte, Inc., a Nevada corporation (the “Company”), and ROBERT
GREIF (“Executive”).

 

The
Company and Executive mutually desire to enter into an agreement containing the terms and conditions pursuant to which the Company
will employ Executive from and after the Effective Date.

 

In
consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto agree as follows:

 

1.       Employment.
The Company shall employ Executive, and Executive hereby accepts employment with the Company, upon the terms and conditions set
forth in this Agreement for the period beginning on the Effective Date and ending as provided in Section 4 hereof (such
period of employment hereunder referred to herein as the “Employment Period”).

 

2.       Position
and Duties.

 

(a)       Position.
During the Employment Period, Executive shall serve as Chief Executive Officer and President of the Company and shall have the
duties, responsibilities, functions and authority customarily associated with such position, subject to the power and authority
of the Company’s Board of Directors (the “Board”) to expand or limit such duties, responsibilities, functions
and authority and to overrule actions of officers of the Company. During the Employment Period, Executive shall render such administrative,
financial and other executive and managerial services to the Company Group as the Board may from time to time direct.

 

(b)       Duties.
During the Employment Period, Executive shall report to the Board and Executive shall devote Executive’s best efforts and
full business time and attention (except for permitted vacation periods and reasonable periods of illness or other incapacity)
to the business and affairs of the Company Group. Executive shall perform his duties, responsibilities and functions to the Company
Group hereunder to the best of his abilities in a diligent, trustworthy, professional and efficient manner and shall comply with
applicable law and the Company Group’s policies and procedures in all material respects. In performing his duties and exercising
his authority under the Agreement, Executive shall support and implement the business and strategic plans approved from time to
time by the Board and shall support and cooperate with the Company Group’s efforts to expand their businesses and operate
profitably and in conformity with the business and strategic plans approved by the Board. So long as Executive is employed by
the Company, Executive shall not, without the prior written consent of the Board, perform other services for compensation. No
later than sixty (60) days after the Effective Date, Executive will also submit to the Board his proposed plans for the long-term
success and strategic direction of the Company Group (the “Report”).

 

(c)       Place
of Performance. The principal place of Executive’s employment shall initially be Tampa, Florida, subject to the
Board’s determination of an appropriate long-term headquarters of the Company. The Company and Executive agree that Executive
shall be permitted to work from his home in Boston, Massachusetts (“Home Office”) until such time as an appropriate
long-term headquarters for the Company has been identified and during the Employment Period, Executive shall be required to travel
from time to time to the Company’s current headquarters in Tampa, Florida as well as its other locations, including Nashville,
Tennessee and Scottsdale, Arizona, in the performance of his duties. Executive agrees that he will make an initial visit to the
Company’s current headquarters in Tampa, Florida and meet with the Company’s current executive team and members of
the Board within the first thirty (30) days of the Employment Period.

 

    	 

     

    

 

3.       Compensation
and Benefits.

 

(a)       Signing
Bonus. Executive shall receive a one-time signing bonus in the total gross amount of $30,000 payable upon the first available
payroll date following the Effective Date.

 

(b)       Base
Salary. During the Employment Period, Executive’s base salary shall be $400,000 per annum (the “Base Salary”),
which Base Salary shall be payable by the Company in regular installments in accordance with the Company’s general payroll
practices (as in effect from time to time). Executive’s Base Salary for any partial year will be based upon the actual number
of days elapsed in such year.

 

(c)       Bonus.
In addition to the Base Salary, during each year ending during the Employment Period, Executive will be eligible to earn an annual
bonus (a “Bonus”) as determined by the Board, in its sole discretion as follows:

 

(i)       2020
Calendar Year. With respect to the calendar year ending December 31, 2020, provided that the Executive is employed
by the Company on the last day of such calendar year, the Executive shall be entitled to a cash bonus equal to $50,000, based
on (A) the timely delivery by Executive of the Report and (ii) other subjective discretionary factors taken into consideration
by the Board.

 

(ii)       Additional
Years. Beginning with the calendar year ending December 31, 2021, provided that the Executive is employed by the Company on
the last day of such calendar year, the Executive shall be entitled to a cash bonus equal to up to 50% of his Base Salary, based
on (A) the achievement of performance objectives (financial or otherwise) to be established by the Board for such calendar year
and (B) other subjective discretionary factors taken into consideration by the Board.

 

Each
Bonus shall be paid to Executive on or before the earlier of (i) fifteen (15) days after the Company’s receipt of the audited
financial statements for such fiscal year or (ii) one hundred twenty (120) days after such fiscal year end.

 

(d)       Equity.
Executive shall receive options to acquire shares of common stock of the Company representing 3% of the Company’s fully
diluted equity as of the grant date (the “Equity Award”), pursuant to the terms and conditions of the Company’s
employee stock option plan and such other terms and restrictions set forth in the grant agreement. The parties will use reasonable
efforts to negotiate and execute such grant agreement within ninety (90) days after the date of this Agreement. The Equity Award
shall vest over a four (4) year period, with 25% of the Equity Award vesting at the end of the one (1) year anniversary of the
date of grant, and the remainder of the Equity Award vesting quarterly thereafter in equal increments over the next three (3)
years.

 

    	-2-

     

    

 

(e)       Other
Benefits. In addition to (but without duplication of) the Base Salary, and the Bonus described above payable to Executive
pursuant to this Section 3, during the Employment Period, Executive shall be entitled to fifteen (15) days of paid time
off per year (in addition to observed holidays) and, subject to applicable eligibility requirements, such other standard benefits
as are approved by the Board and made available to the officers and employees of the Company including:

 

(i)       Participation
in the Company’s 401k Plan;

 

(ii)       Participation
in the Company’s group health insurance plan, with 100% of the premium costs for the Executive to be paid by the Company
(Executive would be responsible for premium costs for any dependents);

 

(iii)       Company-paid
basic life and accidental death & disability insurance coverage up to $250,000;

 

(iv)       Participation
in Company-sponsored dental, vision, life insurance and short-term and long-term disability plans at Executive’s sole expense
in each case; and

 

(v)       Coverage
under the Company’s directors and officers (D&O) liability insurance policy.

 

The
Company reserves the right, in its sole discretion, to adjust Executive’s benefits provided under this Agreement in connection
with adjustments made by the Company to benefits generally offered to the Company’s employees or otherwise as required by
applicable law.

 

(f)       Expenses.
During the Employment Period, the Company shall reimburse Executive for all reasonable out-of-pocket business expenses incurred
by Executive in the course of performing Executive’s duties and responsibilities under this Agreement which are consistent
with the Company’s policies in effect from time to time with respect to travel, entertainment and other business expenses,
subject to the Company’s requirements with respect to reporting and documentation of such expenses (including timely submission
of requests for reimbursement at least once per calendar month). Expense reimbursement under this Section 3(f) includes
Executive’s reasonable and actual out-of-pocket travel, lodging and meal expenses as contemplated by Section 2(c)
as well as a one-time reimbursement for Executive’s reasonable and actual out-of-pocket costs of purchasing a computer,
printer, phone and other office products for his Home Office, subject to a cap of $3,000.

 

(g)       Withholding.
All amounts payable to Executive as compensation hereunder shall be subject to all required and customary tax and payroll withholding
by the Company Group.

 

    	-3-

     

    

 

4.       Term
and Termination.

 

(a)       Term
and Termination. The Employment Period shall begin on the Effective Date and shall end on the first (1st) anniversary of the
Effective Date; provided that the Employment Period shall terminate prior to any such date (i) immediately upon Executive’s
death or Disability, (ii) on a date of termination set forth in a written notice of termination delivered to Executive by the
Company (after determination by its Board) for any reason (whether for Cause or without Cause), or (iii) on a date of termination
set forth in a written notice of Executive’s resignation delivered to the Company by Executive (which date shall be no less
than 60 days after the Company’s receipt of such written notice, unless waived by the Company in writing). Following the
expiration of the Employment Period, this Agreement shall terminate and have no further force and effect but for the provisions
which expressly survive termination in accordance with Section 8 hereof and if Executive remains employed with the Company
following the expiration of the Employment Period and has not entered into a new employment agreement with the Company governing
such continued employment relationship, his continued employment with the Company will be on at “at will” basis.

 

(b)       Termination
without Cause. If the Employment Period is terminated by the Company without Cause (other than as a result of Executive’s
death or Disability) at any time prior to the 12-month anniversary of the Effective Date, Executive shall be entitled to receive:

 

(i)       Executive’s
Base Salary through the date of termination of the Employment Period (such date of termination or expiration, for any reason,
the “Termination Date”);

 

(ii)       any
Bonus pursuant to Section 3(c) previously awarded by the Board, but not yet paid, to Executive in respect of the year that
ended on or prior to the Termination Date, which amount shall be paid at the same time it would have been paid pursuant to Section
3(c);

 

(iii)       reimbursement
of reimbursable expenses incurred on or prior to the Termination Date in accordance with Section 3(f); and

 

(iv)       an
amount equal to the portion of the Base Salary for the remainder of the Employment Period (the “Severance Period”),
which shall be payable by the Company in equal installments over the course of the Severance Period in accordance with the Company’s
normal payroll practices (as in effect from time to time).

 

    	-4-

     

    

 

in
each case, if and only if Executive has executed and delivered to the Company a general release in form and substance
satisfactory to the Company (a “Separation Agreement”) and the Separation Agreement has become effective within
forty (40) days after the Termination Date (the “Required Release Date”), and, in each case, only so long
as Executive has not revoked or breached the provisions of the Separation Agreement or the Restrictive Covenants; and Executive
shall not be entitled to any other salary, bonuses, employee benefits or other compensation after the Termination Date. For the
avoidance of doubt, the Separation Agreement must contain the following basic provisions: (A) general release in favor of the
Company and any other member of the Company Group and each of their respective members, owners, officers, directors, employees,
agents, and contractors; (B) confidentiality; (C) Executive’s duty to reasonably cooperate in transitioning his duties and
work to his successor; (D) Executive’s duty to assist the Company with respect to litigation or investigations concerning
matters about which Executive has knowledge; (E) Executive’s obligation to return all Company property; and (F) a non-competition
restriction as featured in Section 6(a) of this Agreement to be effective in the event that Executive is terminated without
Cause. Notwithstanding anything to the contrary, the payments under this Section 4(b) shall commence on the first payroll
date following the date that such Separation Agreement becomes effective and non-revocable; provided, however, that
such first payment shall include all amounts that otherwise would have been paid prior to the date the first payment was made
had such payments commenced immediately upon employment termination. Notwithstanding the two preceding sentences, to the extent
necessary to comply with Section 409A of the Code, if the Termination Date and Required Release Date are in two separate calendar
years, any payments of amounts under this Section 4(b) that constitute deferred compensation within the meaning of Section
409A of the Code shall be payable on the later of (I) the date such payment is otherwise payable under this Section 4(b)
or (II) the first payroll date in such second calendar year. In any event, if such Separation Agreement is not effective and non-revocable
by the Required Release Date, then Executive shall forfeit all rights to receive any payments under this Section 4(b).

 

(c)       Other
Termination. If the Employment Period is terminated (x) by the Company for Cause, (y) by Executive’s resignation, or
(z) due to Executive’s death, Disability or expiration of the Employment Period, then Executive shall be entitled to receive
only (i) Executive’s Base Salary through the Termination Date, and (ii) reimbursement of reimbursable expenses incurred
on or prior to the Termination Date in accordance with Section 3(f), and Executive shall not be entitled to any other salary,
bonuses, benefits or other compensation after termination of the Employment Period, except as otherwise expressly required under
applicable law.

 

(d)       No
Other Benefits. Except as otherwise expressly provided herein, Executive shall not be entitled to any other salary, bonuses,
employee benefits or compensation from the Company Group after the termination of the Employment Period and all of Executive’s
rights to salary, bonuses, employee benefits and other compensation hereunder which would have accrued or become payable after
the Termination Date (other than vested retirement benefits accrued on or prior to the termination or expiration of the Employment
Period, accrued insurance benefits or other amounts owing hereunder as of the date of such termination or expiration that have
not yet been paid) shall cease upon such termination or expiration, other than as expressly required under applicable law (such
as COBRA). In furtherance of the foregoing, in the event the Company terminates Executive’s employment on the basis that
it is for Cause and it is ultimately determined that such termination was without Cause, it shall not be deemed a breach of this
Agreement and Executive shall only be entitled to the amounts provided for in Section 4(b) in connection with a termination
without Cause.

 

    	-5-

     

    

 

5.       Nondisclosure
and Nonuse of Proprietary Information; Ownership of Intellectual Property.

 

(a)       Protection
of Proprietary Information. Executive acknowledges that the continued success of the Company Group depends upon the use and
protection of a large body of Proprietary Information. Executive agrees that he shall not disclose or use at any time, either
during his employment with the Company or thereafter, any Proprietary Information of which Executive is or becomes aware, whether
or not such information is developed by Executive, except to the extent that such disclosure or use is directly related to and
required by Executive’s performance of duties assigned to Executive by the Board or under this Agreement. Executive shall
take all reasonable and appropriate steps to safeguard Proprietary Information and to protect it against disclosure, misuse, espionage,
loss and theft. The foregoing shall not, however, prohibit disclosure by Executive of Proprietary Information that has been published
in a form generally available to the public prior to the date Executive proposes to disclose such information. Information shall
not be deemed to have been published merely because individual portions of the information have been separately published, but
only if all material features comprising such information have been published in combination. Executive agrees to deliver to the
Company at the end of the Employment Period, or at any other time the Company may request in writing, all copies and embodiments,
in whatever form, of memoranda, notes, plans, records, reports and other documents (and copies thereof), relating to the business
of the Company Group (including, without limitation, all Proprietary Information or Intellectual Property) that he may then possess
or have under his control.

 

(b)       Use
of Confidential Information.

 

(i)       During
the Employment Period, Executive shall not use or disclose any confidential information or trade secrets, if any, of any former
employers or any other Person to whom Executive has an obligation of confidentiality, and shall not bring onto the premises
of the Company Group any unpublished documents or any property belonging to any former employer or any other person to whom Executive
has an obligation of confidentiality unless consented to in writing by the former employer or person. Executive shall use in the
performance of his duties only information that is (i) generally known and used by persons with training and experience comparable
to Executive’s and that is (x) common knowledge in the industry or (y) is otherwise legally in the public domain, (ii) otherwise
provided or developed by the Company Group or (iii) in the case of materials, property or information belonging to any former
employer or other person to whom Executive has an obligation of confidentiality, approved for such use in writing by such former
employer or person. If at any time during this employment with any member of the Company Group, Executive believes he is being
asked to engage in work that will, or will be likely to, jeopardize any confidentiality or other obligations Executive may have
to former employers, Executive shall immediately advise the Board so that Executive’s duties can be modified appropriately.
Executive represents and warrants to the Company that Executive took nothing with him which belonged to any former employer when
Executive left his prior position and that Executive has nothing that contains any information which belongs to any former employer.
If at any time Executive discovers this is incorrect, Executive shall promptly return any such materials to Executive’s
former employer. The Company does not want any such materials, and Executive shall not be permitted to use or refer to any such
materials in the performance of Executive’s duties hereunder.

 

    	-6-

     

    

 

(ii)       Executive
acknowledges and agrees that he is hereby notified of the immunity provisions of Section 1833(b) of the federal Defend Trade Secrets
Act, which provides as follows:

 

IMMUNITY
FROM LIABILITY FOR CONFIDENTIAL DISCLOSURE OF A TRADE SECRET TO THE GOVERNMENT OR IN A COURT FILING.-

 

		1)	IMMUNITY.-An
                                         individual shall not be held criminally or civilly liable under any Federal or State
                                         trade secret law for the disclosure of a trade secret that-(A) is made (i) in confidence
                                         to a Federal, State, or local government official, either directly or indirectly, or
                                         to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected
                                         violation of law; or (B) is made in a complaint or other document filed in a lawsuit
                                         or other proceeding, if such filing is made under seal.
	 	 	 
		2)	USE
                                         OF TRADE SECRET INFORMATION IN ANTI-RETALIATION LAWSUIT.- An individual who files a lawsuit
                                         for retaliation by an employer for reporting a suspected violation of law may disclose
                                         the trade secret to the attorney of the individual and use the trade secret information
                                         in the court proceeding, if the individual-(A) files any document containing the trade
                                         secret under seal; and (B) does not disclose the trade secret, except pursuant to court
                                         order.

 

(c)       Third-Party
Information. Executive understands that the Company Group will receive from third parties confidential or proprietary information
(“Third-Party Information”) subject to a duty on the Company Group’s part to maintain the confidentiality
of such information and to use it only for certain limited purposes. During the Employment Period and thereafter, and without
in any way limiting the provisions of Section 5(a) above, Executive will hold Third-Party Information in the strictest
confidence and will not disclose to anyone (other than personnel of the Company Group who need to know such information in connection
with their work for the Company Group) or use, except in connection with his work for the Company Group, Third-Party Information
unless expressly authorized by a member of the Board in writing.

 

(d)       Intellectual
Property, Inventions and Patents. In the event that Executive during the term of his employment by the Company generates,
authors, conceives, develops, acquires, makes, reduces to practice or contributes to any discovery, formula, Trade Secret, invention,
innovation, improvement, development, method of doing business, process, program, design, analysis, drawing, report, data,
software, firmware, logo, device, method, product or any similar or related information, any copyrightable work or any Proprietary
Information (collectively, “Intellectual Property”), Executive acknowledges that such Intellectual Property
is and shall be the exclusive property of the Company. Any copyrightable work prepared in whole or in part by Executive shall
to be deemed “a work made for hire” to the maximum extent permitted under Section 201(b) of the 1976 Copyright Act
as amended, and the Company shall own all of the rights comprised in the copyright therein. Without limiting the foregoing, Executive
hereby assigns his entire right, title and interest in and to all Intellectual Property to the Company. During and after the term
of Executive’s employment with the Company, Executive shall promptly and fully disclose all Intellectual Property to the
Company and shall cooperate with the Company Group to establish, confirm and protect the Company Group’s interests in and
rights and title to such Intellectual Property (including, without limitation, providing reasonable assistance in securing patent
protection and copyright registrations and executing all documents as reasonably requested by the Company, whether such requests
occur prior to or after termination of Executive’s employment with the Company). Notwithstanding the foregoing, the provisions
of this Section 5(d) shall not apply to, and the Company Group shall have no interest in, any applicable protectable work
of intellectual property that both (i) is not applied commercially and has no commercial application, and (ii) was created or
conceived by Executive outside the scope of his duties and responsibilities to the Company Group and without using the facilities,
resources or equipment of the Company Group.

 

    	-7-

     

    

 

6.       Non-Competition
and Non-Solicitation. Executive acknowledges that in the course of Executive’s employment with the Company Group, Executive
has, and will continue to, become familiar with the Company Group’s trade secrets and with other Proprietary Information
concerning such entities and that Executive’s services have been and will be of special, unique and extraordinary value
to the Company Group. Therefore, in further consideration of the compensation to be paid to Executive hereunder, Executive agrees
that, without limiting any other obligation pursuant to this Agreement:

 

(a)       Non-Compete.
During the Employment Period and for a period thereafter of one (1) year (the “the Non-Compete Period”), Executive
shall not directly or indirectly, either for Executive or for any other Person, own any interest in, manage, control, participate
in, consult with, render services for, finance or in any other manner engage in any business with any Person (including, without
limitation, any division, group or franchise of a larger organization) that engages in the Business anywhere in the United States
or that otherwise competes with the Business. For purposes of this Agreement, the term “participate in” shall include,
without limitation, having any direct or indirect interest in any corporation, partnership, joint venture or other entity, whether
as a sole proprietor, owner, stockholder, member, partner, joint venturer, creditor or otherwise, or rendering any direct or indirect
service or assistance to any individual, corporation, partnership, joint venture and other business entity (whether as a director,
officer, manager, supervisor, employee, agent, consultant or otherwise). For purposes of this Agreement, “Business”
means (i) the business of developing and implementing innovative treatment options to treat chronic lung disease, and (ii) any
other businesses competitive with the businesses of any Company Group member as such businesses exist at the Termination Date.
Nothing herein shall prohibit Executive from owning not more than 5% of the outstanding stock of any class of a corporation that
is publicly traded, so long as Executive has no active participation in the business of such corporation. In the event that Executive
has breached his fiduciary duty to the Company or has unlawfully taken any property belonging to the Company or any other Company
Group member, the Non-Compete Period shall extend to a period of two (2) years after the end of the Employment Period. Executive
acknowledges and agrees that this non-compete restriction in Section 6(a) is necessary because the legitimate business
interests of the Company Group (including but not limited to its trade secrets, confidential and proprietary information, and
goodwill) cannot be adequately protected through alternative restrictive covenants despite their inclusion in this Agreement.

 

    	-8-

     

    

 

(b)       Non-Solicitation.
During the Employment Period and for a period thereafter of two (2) years (the “Protection Period”), Executive
shall not directly or indirectly through another Person (other than on behalf of any Company Group member) (i) induce or attempt
to induce any employee or officer or independent contractor of any member of the Company Group to leave the employ of, or terminate
its affiliation with, the such Company Group member, or in any way interfere with the relationship between such Company Group
member and any such Person, (ii) hire or seek any business affiliation with any Person who was an employee or officer or independent
contractor of any member of the Company Group within one year after such Person ceased to be an officer or employee of such Company
Group member, or (iii) induce or attempt to induce any customer, supplier (including without limitation, Rion, LLC), licensee
or other business relation of any member of the Company Group to cease doing business with such Company Group member, reduce the
business that it does with such Company Group member or in any way interfere with the relationship between any such customer,
supplier, licensee or business relation and any member of the Company Group (including, without limitation, making any negative
statements or communications concerning any member of the Company Group).

 

(c)       Non-Disparagement.
Without limiting any other obligation of Executive pursuant to this Agreement, Executive hereby covenants and agrees that, except
as may be required by applicable law, Executive shall not make or cause to be made any disparaging, negative or critical statements,
written or oral, in any forum or media, regarding the Company or any member of the Company Group or any of their respective executives,
managers, directors, employees, policies, services, products, processes, operations, or facilities either during the Employment
Period or any time after the Employment Period.

 

(d)       Blue-Pencil;
Modification. If, at the time of enforcement of Section 5 or this Section 6, a court shall hold that the duration,
scope or area restrictions stated herein are unreasonable under circumstances then existing, the parties agree that the maximum
duration, scope or area reasonable under such circumstances shall be substituted for the stated duration, scope or area and that
the court shall be allowed to revise the restrictions contained herein to cover the maximum period, scope and area permitted by
law. Executive acknowledges that the restrictions contained in Section 5 and this Section 6 (collectively, the “Restrictive
Covenants” and each, a “Restrictive Covenant”) are reasonable and that he has reviewed the provisions
of this Agreement with his legal counsel.

 

(e)       Enforcement.
Because Executive’s services are unique and because Executive has access to Proprietary Information, the parties hereto
agree that, in the event of the breach or a threatened breach by Executive of any Restrictive Covenant, the Company Group would
suffer irreparable harm and money damages would be an inadequate remedy therefor, and in addition and supplementary to other rights
and remedies existing in its favor, the Company Group shall be entitled to specific performance and/or injunctive or other equitable
relief from a court of competent jurisdiction in order to enforce or prevent any violations of the provisions hereof (without
posting a bond or other security). In addition, in the event of an alleged breach or violation by Executive of any Restrictive
Covenant, (i) the Protection Period shall be tolled until such breach or violation has been duly cured, (ii) the Company Group
shall be entitled to recover from Executive all profit, remuneration or other consideration that Executive gains from breaching
the covenant and damages that the Company suffers as a result of the breach and (iii) the Company Group shall be entitled to reimbursement
of all costs and expenses incurred in enforcing Executive’s obligations hereunder or otherwise defending or prosecuting
any mediation, arbitration or litigation arising out of Executive’s obligations, including premiums for bonds, fees for
experts and investigators, and legal fees, costs and expenses incurred before a lawsuit is filed and in trial, appellate, bankruptcy
and judgment-execution proceedings. Executive acknowledges and agrees that the Company Group may exercise any of the foregoing
remedies concurrently, independently or successively.

 

    	-9-

     

    

 

(f)       Additional
Acknowledgments. Executive acknowledges that the Restrictive Covenants are in mutually agreed upon consideration of: (i) employment
with the Company, (ii) Executive’s opportunity to receive the Equity Award, (iii) the job protections afforded to Executive
under this Agreement, and (iv) additional good and valuable consideration as set forth in this Agreement. In addition, Executive
agrees and acknowledges that the Restrictive Covenants do not preclude Executive from earning a livelihood, nor do they unreasonably
impose limitations on Executive’s ability to earn a living. In addition, Executive acknowledges (x) that the business of
the Company Group will be conducted throughout the United States, (y) notwithstanding the state of organization or principal office
of any member of the Company Group or their respective facilities, or any of their respective executives or employees (including
Executive), it is expected that the Company Group will have business activities and have valuable business relationships within
its industry throughout the United States, and (z) as part of Executive’s responsibilities, Executive will provide services
or have a material presence or influence (including travel) throughout the United States and other jurisdictions where the Company
Group conducts business during the Employment Period in furtherance of the Company Group’s business and its relationships.
Executive agrees and acknowledges that the potential harm to the Company Group of the non-enforcement of any Restrictive Covenant
outweighs any potential harm to Executive of its enforcement by injunction or otherwise. Executive acknowledges that he has carefully
read this Agreement, is hereby advised of his right to consult with legal counsel prior to signing this Agreement, and in fact
has consulted with legal counsel of Executive’s choosing regarding its contents, has given careful consideration to the
restraints imposed upon Executive by this Agreement and is in full accord as to their necessity for the reasonable and proper
protection of the trade secrets, confidential and proprietary information, and goodwill of the Company Group now existing or to
be developed in the future. Executive expressly acknowledges and agrees that each and every Restrictive Covenant imposed by this
Agreement is reasonable with respect to subject matter, scope of activities, time period and geographical area. Executive acknowledges
and agrees that a draft of this Agreement (including the provisions in this Section 6) have been provided to him by the
earlier of a formal offer of employment or ten (10) business days before the commencement of his employment.

 

(g)       All
of the Restrictive Covenants are intended by each party hereto to be, and shall be construed as, agreements independent of any
other obligation or provision in this Agreement, and the existence of any claim or cause of action of Executive against the Company,
whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement by the Company of any Restrictive
Covenant.

 

7.       Executive’s
Representations. Executive hereby represents and warrants to the Company that (a) the execution, delivery and performance
of this Agreement by Executive do not and shall not conflict with, breach, violate or cause a default under any contract, agreement,
instrument, order, judgment or decree to which Executive is a party or by which Executive is bound, (b) Executive is not a party
to or bound by any employment agreement, non-compete agreement or confidentiality agreement with any other person or entity and
(c) upon the execution and delivery of this Agreement by the Company, this Agreement shall be the valid and binding obligation
of Executive, enforceable in accordance with its terms. Executive hereby acknowledges and represents that Executive has consulted
with independent legal counsel regarding Executive’s rights and obligations under this Agreement and that Executive fully
understands the terms and conditions contained herein.

 

    	-10-

     

    

 

8.       Survival.
Sections 4 through 23 (other than Section 21), inclusive, shall survive and continue in full force in accordance
with their terms notwithstanding the expiration or termination of the Employment Period.

 

9.       Notices.
Any notice provided for in this Agreement shall be in writing and shall be either personally delivered, sent by reputable overnight
courier service or mailed by first class mail, return receipt requested, to the recipient at the address below indicated:

 

Notices
to Executive:

 

Executive’s
most recent home address on file with the Company. 

 

Notices
to the Company Group or any of its members:

 

H-Cyte,
Inc.

201
E. Kennedy Blvd, Suite 700

Tampa,
Florida 33602

Attn:
    Board of Directors

 

with
a copy to (which shall not constitute notice):

 

Hill,
Ward & Henderson, P.A.

101
E. Kennedy Boulevard, 37th Floor

Tampa,
FL 33602

Attn:    S.
Gordon Hill

 

or
such other address or to the attention of such other person as the recipient party shall have specified by prior written notice
to the sending party. Any notice under this Agreement shall be deemed to have been given when so delivered, sent or mailed.

 

10.       Severability.
Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable
law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision of this
Agreement or any action in any other jurisdiction, but this Agreement shall be reformed, construed and enforced in such jurisdiction
as if such invalid, illegal or unenforceable provision had never been contained herein.

 

11.       Complete
Agreement. This Agreement and those documents expressly referred to herein embody the complete agreement and understanding
among the parties and supersede and preempt any prior understandings, agreements or representations by or among the parties, written
or oral, which may have related to the subject matter hereof in any way.

 

    	-11-

     

    

 

12.       No
Strict Construction. The language used in this Agreement shall be deemed to be the language chosen by the parties hereto to
express their mutual intent, and no rule of strict construction shall be applied against any party.

 

13.       Counterparts.
This Agreement may be executed in separate counterparts (including by means of facsimile and electronic transmission in portable
document format (.pdf)), each of which is deemed to be an original and all of which taken together constitute one and the same
agreement.

 

14.       Successors
and Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive, the Company and
their respective heirs, successors and assigns, except that Executive may not assign his rights or delegate his duties or obligations
hereunder without the prior written consent of the Company.

 

15.       Choice
of Law; Attorneys’ Fees. All issues and questions concerning the construction, validity, enforcement and interpretation
of this Agreement and the exhibits and schedules hereto shall be governed by, and construed in accordance with, the laws of the
State of Florida, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Florida
or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Florida. If
any action at law or in equity (including any arbitration) is commenced to enforce or interpret the terms of any provision of
this Agreement, the prevailing party shall be entitled to reasonable attorney’s fees, costs and disbursements in addition
to any other relief to which such party may be entitled.

 

16.       Amendment
and Waiver. The provisions of this Agreement may be amended or waived only with the prior written consent of the Company (as
approved by the Board) and Executive, and no course of conduct or course of dealing or failure or delay by any party hereto in
enforcing or exercising any of the provisions of this Agreement (including, without limitation, the Company’s right to terminate
the Employment Period for Cause) shall affect the validity, binding effect or enforceability of this Agreement or be deemed to
be an implied waiver of any provision of this Agreement.

 

17.       Insurance.
The Company may, at its discretion, apply for and procure in its own name and for its own benefit life and/or disability insurance
on Executive in any amount or amounts considered advisable. Executive agrees to cooperate in any medical or other examination,
supply any information and execute and deliver any applications or other instruments in writing as may be reasonably necessary
to obtain and constitute such insurance. Executive hereby represents that Executive has no reason to believe that Executive’s
life is not insurable at rates now prevailing for healthy men of Executive’s age.

 

18.       Indemnification
and Reimbursement of Payments on Behalf of Executive; Section 409A.

 

(a)       The
Company shall be entitled to deduct or withhold from any amounts owing from the Company Group to Executive any federal, state,
local or foreign withholding taxes, excise tax, or employment taxes (“Taxes”) imposed with respect to Executive’s
compensation or other payments from the Company Group or Executive’s ownership interest in the Company (including, without
limitation, wages, bonuses, dividends, the receipt or exercise of equity options and/or the receipt or vesting of restricted equity).

 

    	-12-

     

    

 

(b)       To
the extent necessary to comply with Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”),
for purposes of determining Executive’s entitlement to payments or benefits required to be paid under this Agreement on
account of a termination of Executive’s employment, “termination of employment” and variations thereof shall
mean Executive’s “separation from service” from the Company within the meaning of Section 409A(a)(2)(A)(i) of
the Code and the default rules of Treasury Regulations Section 1.409A-1(h) promulgated thereunder, and the “Termination
Date” shall be the date of Executive’s separation from service. This Agreement is intended to comply with the requirements
of Section 409A of the Code, and the parties hereby agree to use reasonable efforts to amend this Agreement as and when necessary
to conform to or otherwise properly reflect any guidance issued under Section 409A of the Code after the date hereof without violating
Section 409A of the Code in a manner that preserves the original intent of the parties to the maximum extent possible. The Company
does not guarantee that this Agreement, or the administration thereof, does or will comply with Section 409A of the Code, and
it will have no liability for any claim, loss, liability or expense of Executive or any other Person arising out of any interest,
penalties or additional taxes as a result of this Agreement or the administration thereof not satisfying any of the requirements
of Section 409A of the Code. All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in
accordance with the requirements of Section 409A of the Code to the extent that such reimbursements or in-kind benefits are subject
to Section 409A of the Code. Whenever payments under this Agreement are to be made in installments, each such installment shall
be treated as a separate payment for purposes of Section 409A of the Code.

 

19.       Consent
to Jurisdiction. EACH OF THE PARTIES IRREVOCABLY SUBMITS TO THE NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS
LOCATED IN HILLSBOROUGH COUNTY, FLORIDA AND EACH OF THE FEDERAL AND STATE COURTS HAVING APPEALS JURISDICTION WITH RESPECT THERETO
FOR THE PURPOSES OF ANY SUIT, ACTION OR OTHER PROCEEDING ARISING OUT OF THIS AGREEMENT, ANY RELATED AGREEMENT OR ANY TRANSACTION
CONTEMPLATED HEREBY OR THEREBY. EACH OF THE PARTIES HERETO FURTHER AGREES THAT SERVICE OF ANY PROCESS, SUMMONS, NOTICE OR DOCUMENT
BY U.S. REGISTERED MAIL TO SUCH PARTY’S RESPECTIVE ADDRESS SET FORTH ABOVE SHALL BE EFFECTIVE SERVICE OF PROCESS FOR ANY
ACTION, SUIT OR PROCEEDING IN HILLSBOROUGH COUNTY, FLORIDA WITH RESPECT TO ANY MATTERS TO WHICH IT HAS SUBMITTED TO JURISDICTION
IN THIS SECTION 19. EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY OBJECTION TO THE LAYING OF VENUE
OF ANY ACTION, SUIT OR PROCEEDING ARISING OUT OF THIS AGREEMENT, ANY RELATED DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY
OR THEREBY IN THE STATE AND FEDERAL COURTS LOCATED IN HILLSBOROUGH COUNTY, FLORIDA AND EACH OF THE FEDERAL AND STATE COURTS HAVING
APPEALS JURISDICTION WITH RESPECT THERETO, AND HEREBY FURTHER IRREVOCABLY AND UNCONDITIONALLY WAIVES AND AGREES NOT TO PLEAD OR
CLAIM IN ANY SUCH COURT THAT ANY SUCH ACTION, SUIT OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT
FORUM.

 

    	-13-

     

    

 

20.       Waiver
of Jury Trial. As a specifically bargained for inducement for each of the parties
hereto to enter into this Agreement (after having the opportunity to consult with counsel), each
party hereto expressly waives, TO THE MAXIMUM EXTENT ALLOWED BY APPLICABLE LAW, the right to trial by jury in any lawsuit or proceeding
relating to or arising in any way from this Agreement or the matters contemplated hereby.

 

21.       Corporate
Opportunity. During the Employment Period, Executive shall submit to the Board all business, commercial and investment opportunities
or offers presented to Executive or of which Executive becomes aware which relate to the business of the Company Group at any
time during the Employment Period (“Corporate Opportunities”). During the Employment Period, unless approved
by the Board, Executive shall not accept or pursue, directly or indirectly, any Corporate Opportunities on Executive’s own
behalf.

 

22.       Executive’s
Cooperation. During the Employment Period and thereafter, Executive shall cooperate with the Company Group in any internal
investigation, any administrative, regulatory or judicial investigation or proceeding or any dispute with a third party as reasonably
requested by the Company Group (including, without limitation, Executive being available to the Company Group upon reasonable
notice for interviews and factual investigations, appearing at the Company Group’s request to give testimony without requiring
service of a subpoena or other legal process, volunteering to the Company Group all pertinent information and turning over to
the Company Group all relevant documents which are or may come into Executive’s possession, all at times and on schedules
that are reasonably consistent with Executive’s other permitted activities and commitments). In the event the Company Group
requires Executive’s cooperation in accordance with this Section 22 following the termination of the Employment Period,
the Company shall pay Executive a per diem reasonably determined by the Board and reimburse Executive for reasonable expenses
incurred in connection therewith (including lodging and meals, upon submission of receipts).

 

23.       Definitions.
For purposes of this Agreement, the following terms shall have the meanings set forth below:

 

“Affiliate”
means, with respect to the Company and its Subsidiaries, any other Person controlling, controlled by or under common control with
the Company or any of its Subsidiaries and, in the case of a Person which is a partnership, any partner of the Person. Notwithstanding
anything to the contrary in this Agreement, Executive shall not be deemed an Affiliate of the Company or any of its Subsidiaries.

 

    	-14-

     

    

 

“Cause”
means with respect to Executive one or more of the following: (i) the conviction of or plea of no contest to a felony or other
crime involving moral turpitude or any other crime involving misappropriation, embezzlement or fraud, (ii) insubordination, willful
misconduct or gross negligence in the performance of Executive’s duties under this Agreement or any breach of fiduciary
duty owed to any member of the Company Group or its owners, (iii) unexcused, intentional or repeated failure to perform material
assigned duties (that are materially consistent with the responsibilities and duties of Executive’s title or under this
Agreement) for any member of the Company Group, (iv) any act or omission aiding or abetting a competitor, supplier or customer
of any member of the Company Group to the material disadvantage or detriment of such Company Group member, (v) Executive’s
appropriation or attempted appropriation of opportunities for Executive’s own advantage or other conflicts of interest where
Executive acts for his own personal benefit, instead of for the benefit of the Company Group, (vi) substance abuse or use of illegal
substances while performing duties, in the workplace or that otherwise materially impairs Executive’ ability to perform
his responsibilities hereunder or results in material harm to any member of the Company Group or its owners (for purposes of clarity,
the mere consumption of alcohol in a reasonable manner at Company social events does not constitute substance abuse) or the unlawful
sale, use, or distribution of illegal or controlled substances by Executive, (vii) Executive breaches any confidentiality, non-competition,
non-solicitation or non-disparagement covenant applicable to Executive, or (viii) a good faith determination by the Board that
any other material breach of the this Agreement has occurred, and such breach is incurable or is not cured to the Board’s
reasonable satisfaction within 30 days after written notice thereof to Executive (it being understood Executive may be suspended
(with pay only if such breach is ultimately so cured and without pay otherwise) during such 30-day period and there is no cure
period for a violation of any restrictive covenants). It is agreed and understood that mere underperformance or substandard performance
of the Company Group is not intended to and shall not provide an independent basis for termination for Cause. The determination
as to whether Cause exists for purposes of this Agreement will be made by the Board in its sole discretion.

 

“Company
Group” means the collectively, the Company, its Subsidiaries, and their respective Affiliates.

 

“Disability”
means that, as a result of his incapacity due to physical or mental illness, Executive is considered disabled under the Company’s
long-term disability insurance plans or, in the absence of such plans, Executive is unable to perform the essential duties, responsibilities
and functions of his position with the Company for either sixty (60) consecutive days or ninety (90) days in any rolling twelve
(12) month period as a result of any mental or physical disability or incapacity even with reasonable accommodations of such disability
or incapacity provided by the Company or if providing such accommodations would be unreasonable, all as determined by the Board
in its good faith judgment. Executive shall cooperate in all respects with the Company if a question arises as to whether he has
a Disability (including, without limitation, submitting to an examination by a medical doctor or other health care specialists
selected by the Company and authorizing such medical doctor or such other health care specialist to discuss Executive’s
condition with the Company).

 

“Person”
means an individual, a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust,
a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof.

 

    	-15-

     

    

 

“Proprietary
Information” means all information of a confidential or proprietary nature (whether or not specifically labeled or identified
as “confidential” and now existing or to be developed in the future), in any form or medium, that relates to or results
from the business, historical or projected financial results, products, services or research or development of the Company Group
or their respective suppliers, distributors, customers, independent contractors or other business relations. Proprietary Information
will be interpreted as broadly as possible to include all information of any sort (whether merely remembered or embodied in a
tangible or intangible form) that is (I) related to the Company Group’s (including their predecessors’ prior to being
acquired by the Company) current or potential business and (II) is not generally or publicly known. Proprietary Information includes,
but is not limited to, the following: (i) internal business information (including historical and projected financial information
and budgets and information relating to strategic and staffing plans and practices, including plans regarding planned and potential
sales, financial and business plans, training, marketing, promotional and sales plans and practices, cost, rate and pricing structures
and prices and terms, risk management practices, negotiation strategies and practices, accounting and business methods, acquisition
opportunities, development, transition and transformation plans, locations of sales representatives, customer service, integration
processes and requirements and costs of providing service, support and equipment); (ii) identities of, individual requirements
of, specific contractual arrangements with, and information about, the Company Group’s current, former or prospective employees
(including personnel files and other information), suppliers, distributors, customers, independent contractors or other business
relations and their confidential information; (iii) Trade Secrets, technology, know-how, compilations of data and analyses, techniques,
systems, formulae, research, records, reports, manuals, flow charts, documentation, models, data and data bases relating thereto;
(iv) computer software, including operating systems, applications and program listings; (v) inventions, innovations, ideas, devices,
improvements, developments, methods, processes, designs, analyses, drawings, photographs, reports and all similar or related information
(whether or not patentable and whether or not reduced to practice); (vi) copyrightable works, (vii) intellectual property of every
kind and description, and (viii) all similar and related information in whatever form.

 

“Severance
Period” means the number of full calendar months between the Termination Date and the date that is the one-year anniversary
of the Effective Date.

 

“Subsidiary”
or “Subsidiaries” means any Person of which (i) if a corporation, a majority of the total voting power of shares
of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers, or trustees
thereof is at the time owned or controlled, directly or indirectly, by the Company or one or more of the other Subsidiaries of
the Company or a combination thereof or (ii) if a limited liability company, partnership, association or other business entity
(other than a corporation), a majority of partnership or other similar ownership interest thereof is at the time owned or controlled,
directly or indirectly, by the Company or one or more Subsidiaries of the Company or a combination thereof and for this purpose
a Person or Persons owns a majority ownership interest in such a business entity (other than a corporation) if such Person or
Persons shall be allocated a majority of such business entity’s gains or losses or shall be or control any managing director
or general partner of such business entity (other than a corporation). For the purposes hereof, the term Subsidiary shall include
all Subsidiaries of such Subsidiary.

 

“Trade
Secrets” means the trade secrets and other Proprietary Information (as defined above) that the Company Group has made
reasonable efforts to keep confidential and that derive independent economic value, actual or potential, from not being generally
known to the public or to other persons who can obtain economic value from its disclosure or use.

 

*
* * * *

 

    	-16-

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the date first written above.

 

	 	Company:
	 	 
	 	H-CYTE,
INC.
	 	 
	 	By:	/s/ Raymond
    Monteleone
	 	Name:	Raymond
    Monteleone
	 	Title:	Director

 

	 	Executive:
	 	 
	 	/s/
    Robert Greif
	 	ROBERT
    GREIF

 

Signature
Page to Employment AgreementExhibit 4.1

 

WARRANT
AGREEMENT

 

 THIS
WARRANT AGREEMENT (this “Agreement”), dated as of September 24, 2020, is by and between FinTech Acquisition
Corp. IV, a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company,
a New York limited purpose trust company, as warrant agent (the “Warrant Agent,” also referred to as
the “Transfer Agent”).

 

WHEREAS,
the Company has entered into that certain Unit Subscription Agreement, dated September 24, 2020, with FinTech Investor Holdings
IV, LLC, a Delaware limited liability company (together with FinTech Masala Advisors IV, LLC, the “Sponsor”),
pursuant to which the Sponsor will purchase an aggregate of 610,000 Units (as defined below) for a purchase price of $6,100,000
(“Placement Units”), each Unit consisting of one share of Common Stock (as defined below) (“Placement
Shares”) and one-third of one warrant to purchase one Placement Share (the “Placement Warrants”)
of the Company, and, in connection therewith, has determined to issue and deliver up to 203,333 Placement Warrants bearing the
legend set forth in Exhibit B hereto, to be sold simultaneously with the closing of the Offering (as defined below);

 

WHEREAS,
in order to finance the Company’s transaction costs in connection with an intended initial Business Combination (as defined
below), the Sponsor or an affiliate of the Sponsor or certain of the Company’s executive officers and directors may, but
are not obligated to, loan to the Company funds as the Company may require, of which up to $1,500,000 of such loans may be convertible
into Units at a price of $10.00 per Unit, each Unit consisting of one share of Common Stock and one-third of one warrant to purchase
one share of Common Stock (the “Working Capital Warrants”);

 

WHEREAS,
the Company is engaged in an initial public offering (the “Offering”) of units of the Company’s
equity securities, each such unit comprised of one share of Common Stock and one-third of one Public Warrant (as defined below)
(the “Public Units”, and together with the Placement Units, the “Units”) and,
in connection therewith, has determined to issue and deliver up to 7,666,666 Warrants (including up to 1,000,000 warrants that
may be issuable upon the exercise of a forty-five (45) day over-allotment option granted to the underwriters (the “Over-allotment
Option”)) to investors in the Offering (the “Public Warrants” and, together with the Placement
Warrants and Working Capital Warrants, (the “Warrants”), each whole Warrant evidencing the right of
the holder thereof to purchase one share of Class A common stock of the Company, $0.0001 par value per share (the “Common
Stock”), for $11.50 per share, subject to adjustment as described herein;

 

WHEREAS,
the Company has filed with the Securities and Exchange Commission (the “Commission”) a registration
statement on Form S-1, No. 333-248664 (the “Registration Statement”) and prospectus (the “Prospectus”)
under the Securities Act of 1933, as amended (the “Securities Act”), with respect to the Public Units
and the Public Warrants and Common Stock included in the Public Units;

 

WHEREAS,
the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing so to act, in connection
with the issuance, registration, transfer, exchange, redemption and exercise of the Warrants;

 

WHEREAS,
the Company desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised,
and the respective rights, duties, obligations and immunities of the Company, the Warrant Agent, and the holders of the Warrants;
and

 

WHEREAS,
all acts and things have been done and performed which are necessary to make the Warrants, when executed on behalf of the Company
and countersigned by or on behalf of the Warrant Agent, as provided herein, the valid, binding and legal obligations of the Company,
and to authorize the execution and delivery of this Agreement.

 

     

     

    

 

NOW,
THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows:

 

1.
Appointment of Warrant Agent. The Company hereby appoints the Warrant Agent to act as agent for the Company in connection
with the Warrants, and the Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance with the
terms and conditions set forth in this Agreement.

 

2.
Warrants.

 

2.1
Form of Warrant. Each Warrant shall be issued in registered form only and shall be in substantially the form of Exhibit A
hereto, the provisions of which are incorporated herein and shall be signed by, or bear the original or facsimile signature
of, the Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Secretary or other principal officer
of the Company. In the event the person whose original or facsimile signature has been placed upon any Warrant shall have ceased
to serve in the capacity in which such person signed the Warrant before such Warrant is issued, it may be issued with the same
effect as if he or she had not ceased to be such at the date of issuance.

 

2.2
 Effect of Countersignature. If a physical certificate is issued, unless and until countersigned by the Warrant Agent
pursuant to this Agreement, a Warrant shall be invalid and of no effect and may not be exercised by the holder thereof.

 

2.3
 Registration.

 

2.3.1
Warrant Register. The Warrant Agent shall maintain books (the “Warrant Register”), for the registration
of original issuance and the registration of transfer of the Warrants. Except for fractional Warrants that are included in a Unit
that has not been separated into its constituent securities, no fractional Warrants may be transferred unless accompanied by other
fractional Warrants to be transferred that, in the aggregate allow for the purchase of one full placement share or an integral
multiple thereof (collectively “Whole Warrants” or individually a “Whole Warrant”).
Upon the initial issuance of the Warrants, the Warrant Agent shall issue and register the Warrants in the names of the respective
holders thereof in such denominations and otherwise in accordance with instructions delivered to the Warrant Agent by the Company.
All of the Public Warrants shall initially be represented by one or more book-entry certificates (each, a “Book-Entry
Warrant Certificate”) deposited with The Depository Trust Company (the “Depositary”) and
registered in the name of Cede & Co., a nominee of the Depositary. Ownership of beneficial interests in the Public Warrants
shall be shown on, and the transfer of such ownership shall be effected through, records maintained by (i) the Depositary or its
nominee for each Book-Entry Warrant Certificate, or (ii) institutions that have accounts with the Depositary (each such institution,
with respect to a Warrant in its account, a “Participant”).

 

If
the Depositary subsequently ceases to make its book-entry settlement system available for the Public Warrants, the Company may
instruct the Warrant Agent regarding making other arrangements for book-entry settlement. In the event that the Public Warrants
are not eligible for, or it is no longer necessary to have the Public Warrants available in, book-entry form, the Warrant Agent
shall provide written instructions to the Depositary to deliver to the Warrant Agent for cancellation each Book-Entry Warrant
Certificate, and the Company shall instruct the Warrant Agent to deliver to the Depositary definitive certificates in physical
form evidencing such Warrants (“Definitive Warrant Certificate”). Such Definitive Warrant Certificate
shall be in the form annexed hereto as Exhibit A, with appropriate insertions, modifications and omissions, as provided
above.

 

2.3.2
 Registered Holder. Prior to due presentment for registration of transfer of any Whole Warrant, the Company and the
Warrant Agent may deem and treat the person in whose name such Whole Warrants are registered in the Warrant Register (the “Registered
Holder”) as the absolute owner of such Warrant and of each Warrant represented thereby (notwithstanding any notation
of ownership or other writing on the Warrant Certificate (as defined below) made by anyone other than the Company or the Warrant
Agent), for the purpose of any exercise thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall
be affected by any notice to the contrary.

 

    2

     

    

 

2.4
Detachability of Warrants. The Common Stock and Public Warrants comprising the Public Units shall begin separate trading
on the 52nd day following the date of the Prospectus, or, if such 52nd day is not on a Business Day (as defined below), then on
the immediately succeeding Business Day following such date (the “Detachment Date”), unless Cantor,
acting as representative of the Underwriters, informs the Company of its decision to allow earlier separate trading, but in no
event shall the Common Stock and the Public Warrants comprising the Units be separately traded until (a) the Company has
filed a Current Report on Form 8-K with the Commission that includes an audited balance sheet reflecting receipt by the Company
of the gross proceeds of the Offering and (b) the Company issues a press release announcing when such separate trading shall
begin; provided, however, that, if the Over-allotment Option is exercised following the filing of the initial Current Report on
Form 8-K, a second or amended Current Report on Form 8-K shall be filed by the Company to provide updated financial information
to reflect the exercise of the Over-allotment Option. As used herein, “Business Day” shall mean any
day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions or trust companies are authorized
or obligated by law to close in New York City. Notwithstanding the foregoing, no fractional Warrants will be issued upon the separation
of the Units. If, upon the separation of Public Warrants from Units or otherwise, a holder of Public Warrants would be entitled
to receive a fractional Public Warrant, the Company shall round down to the nearest whole number the number of Public Warrants
to be issued to such holder.

 

2.5
Warrant Attributes.

 

2.5.1 Placement
Warrants and Working Capital Warrants. The Placement Warrants and Working Capital Warrants shall be identical to the
Public Warrants, except that so long as they are held by the Sponsor or any of its respective Permitted Transferees (as
defined below), the Placement Warrants and the Working Capital Warrants: (i) may be exercised for cash or on a cashless
basis, pursuant to subsection 3.3.1(c) hereof, (ii) may not be transferred, assigned or sold until thirty
(30) days after the completion by the Company of an initial Business Combination (as defined below), and
(iii) shall not be redeemable by the Company; provided, however, that in the case of (ii), the Placement
Warrants and the Working Capital Warrants and any shares of Common Stock held by the Sponsor, Cantor or any Permitted
Transferees, and issued upon exercise of the Placement Warrants and the Working Capital Warrants, may be transferred by the
holders thereof to a Permitted Transferee. Further, the period during which the Placement Warrants held by Cantor are
exercisable may not be extended (pursuant to the last sentence of Section 3.2 or otherwise) beyond the date that is five
years from the effective date of the Registration Statement. A “Permitted Transferee” is hereby defined as
any transferee receiving securities in the following transactions:

 

(a)
to the Sponsor (the “Initial Stockholders”) and the Company’s officers or directors;

 

(b)
to an affiliate or immediate family member of any of the Company’s officers, directors and Initial Stockholders;

 

(c)
to any member, officer or director of the Sponsor, or any immediate family member, partner, affiliate or employee of a member
of the Sponsor;

 

(d)
by gift to any Permitted Transferee under any of the immediately preceding subsections (a) through (c), to a trust, the beneficiaries
of which consist entirely of one or more Permitted Transferees under any of the immediately preceding subsections (a) through
(c), or to a charitable organization;

 

(e)
by virtue of laws of descent and distribution upon the death of any officer or director of the Company, Initial Stockholder, member
of the Sponsor, or any officer, director or direct or indirect equityholders of Cantor;

 

(f)
pursuant to a qualified domestic relations order;

 

(g)
in the event of the Company’s liquidation prior to consummation of the Company’s initial business combination;

 

(h)
by virtue of the laws of Delaware, pursuant to the limited liability company agreement of the Sponsor upon dissolution of the
Sponsor;

 

(i)
subsequent to the Company’s consummation of its initial business combination, upon and in connection with the liquidation,
merger, stock exchange or other similar transaction which results in all of the Company’s stockholders having the right
to exchange their shares of common stock for cash, securities or other property;

 

    3

     

    

 

(j)
subsequent to the Company’s consummation of its initial business combination, in the event of a consolidation, merger, stock
exchange or other similar transaction in which the Company is the surviving entity that results in a change in the majority of
the Company’s board of directors or management team; or

 

(k)
through private sales or transfers made in connection with any forward purchase agreement or similar arrangement or in connection
with the consummation of the Company’s initial business combination at prices no greater than the price at which the Placement
Warrants or Working Capital Warrants were originally purchased;

 

provided,
however, that in the case of clauses (a) through (f), (h) and (k) these Permitted Transferees must enter into a written agreement
agreeing to be bound by the restrictions on transfer in this Agreement.

 

3.
Terms and Exercise of Warrants.

 

3.1
Warrant Price. Each Whole Warrant shall entitle the Registered Holder thereof, subject to the provisions of such Warrant
and of this Agreement, to purchase from the Company the number of shares of Common Stock stated therein, at the price of $11.50
per share, subject to the adjustments provided in Section 4 hereof and in the last sentence of this Section 3.1. The
term “Warrant Price” as used in this Agreement shall mean the price per share at which a share of Common
Stock may be purchased pursuant to the Whole Warrant at the time such Whole Warrant is exercised. The Company in its sole discretion
may reduce the Warrant Price at any time prior to the Expiration Date (as defined below) for a period of not less than twenty
(20) Business Days, by providing at least twenty (20) days prior written notice of such reduction to each Registered
Holder. Any such reduction shall be identical among all of the Warrants.

 

3.2
 Duration of Warrants. A Whole Warrant may be exercised only during the period (the “Exercise Period”)
commencing on the later of: (a)  thirty (30) days after the first date on which the Company consummates an acquisition,
through a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with
one or more businesses (a “Business Combination”), or (b)  12 months from the date of the
completion of the Offering (excluding any exercise of the underwriters’ over-allotment option), and terminating at 5:00
p.m., New York City time, on the earlier of (x) five years after the date on which the Company consummates its initial Business
Combination, (y) the liquidation of the Company or, if the Company fails to consummate a Business Combination, 24 months
from the date of completion of the Offering (excluding any exercise of the underwriters’ over-allotment option), or (z) 
with respect to all the Warrants except the Placement Warrants and the Working Capital Warrants, the Redemption Date (as defined
below) (the “Expiration Date“); provided, however, that the exercise of any Warrant shall be subject
to the satisfaction of any applicable conditions, as set forth in subsection 3.3.3 below with respect to an effective
registration statement. Except with respect to the right to receive the Redemption Price (as defined below) (other than with respect
to a Placement Warrant or a Working Capital Warrant to the extent then held by the original purchasers thereof or their Permitted
Transferees) in the event of a redemption (as set forth in Section 6 hereof), each outstanding Warrant (other
than a Placement Warrant or a Working Capital Warrant in the event of a redemption to the extent then held by the original purchasers
thereof or their Permitted Transferees) not exercised on or before the Expiration Date shall become void, and all rights thereunder
and all rights in respect thereof under this Agreement shall cease at 5:00 p.m. New York City time on the Expiration Date.
The Company in its sole discretion may extend the duration of the Warrants by delaying the Expiration Date; provided, that
the Company shall provide at least twenty (20) days prior written notice of any such extension to Registered Holders of the
Warrants and, provided further that any such extension shall be identical in duration among all the Warrants.

 

    4

     

    

 

3.3
Exercise of Warrants.

 

3.3.1
Payment. Subject to the provisions of the Warrant and this Agreement, a Whole Warrant may be exercised by the Registered
Holder thereof by delivering to the Warrant Agent at its corporate trust department (i) the Definitive Warrant Certificate evidencing
the Warrants to be exercised, or, in the case of a Book-Entry Warrant Certificate, the Warrants to be exercised on the records
of the Depositary to an account of the Warrant Agent at the Depositary designated for such purposes in writing by the Warrant
Agent to the Depositary from time to time, (ii) an election to purchase shares of Common Stock pursuant to the exercise of a Warrant,
properly completed and executed by the Registered Holder on the reverse of the Definitive Warrant Certificate or, in the case
of a Book-Entry Warrant Certificate, properly delivered by the Participant in accordance with the Depositary’s procedures,
and (iii) payment in full of the Warrant Price for each full share of Common Stock as to which the Warrant is exercised and any
and all applicable taxes due in connection with the exercise of the Warrant, the exchange of the Warrant for the shares of Common
Stock and the issuance of such shares of Common Stock, as follows:

 

(a) by
wire transfer of immediately available funds in good certified check or good bank draft payable to the order of the Warrant Agent;

 

(b) upon
a redemption pursuant to Section 6 hereof in which the Company’s board of directors (the “Board”)
has elected to require all holders of the Warrants to exercise such Warrants on a “cashless basis,” by surrendering
the Warrant for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number
of shares of Common Stock underlying the Warrant, multiplied by the difference between the Warrant Price and the “Fair Market
Value” (as defined in this subsection 3.3.1(b)) by (y) the Fair Market Value. Solely for purposes of this subsection
3.3.1(b) and Section 6.3, “Fair Market Value” shall mean the average last sale price per share of the Common
Stock for the ten (10) trading day period ending on the third trading day prior to the date on which the notice of redemption
is sent to the holders of the Warrants;

 

(c) with
respect to any Placement Warrant or Working Capital Warrants, so long as such Placement Warrant or Working Capital Warrant is
held by the Sponsor, Cantor or their Permitted Transferees, exercised on a “cashless basis,” by surrendering the Warrants
for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number of shares
of Common Stock underlying the Warrants, multiplied by the difference between the Warrant Price and the “Fair Market Value”,
as defined in this subsection 3.3.1(c), by (y) the Fair Market Value. Solely for purposes of this subsection 3.3.1(c), the
“Fair Market Value” shall mean the average last sale price of the Common Stock for the ten (10) trading day period
ending on the third trading day prior to the date on which notice of exercise of the Warrant is sent to the Warrant Agent; or

 

(d) as
provided in Section 7.4 hereof.

 

3.3.2
Exercise of Fractional Warrants Not Permitted. No fractional Warrant shall be exercisable or redeemable in any manner unless
accompanied by other fractional Warrants to be exercised or redeemed that, in the aggregate for all such fractional Warrants,
constitute a Whole Warrant or Whole Warrants. 

 

3.3.3
Issuance of Shares of Common Stock on Exercise. As soon as practicable after the exercise of any Whole Warrant and the
clearance of the funds in payment of the Warrant Price (if payment is pursuant to subsection 3.3.1(a)), the Company
shall issue to the Registered Holder of such Warrant a book-entry position or certificate, as applicable, for the number of full
shares of Common Stock to which he, she or it is entitled, registered in such name or names as may be directed by him, her or
it, and if such Warrant shall not have been exercised in full, a new book-entry position or countersigned Warrant, as applicable,
for the number of shares of Common Stock as to which such Warrant shall not have been exercised. If fewer than all the Warrants
evidenced by a Book-Entry Warrant Certificate are exercised, a notation shall be made to the records maintained by the Depositary,
its nominee for each Book-Entry Warrant Certificate, or a Participant, as appropriate, evidencing the balance of the Warrants
remaining after such exercise. Notwithstanding the foregoing, the Company shall not be obligated to deliver any shares of Common
Stock pursuant to the exercise of a Warrant and shall have no obligation to settle such Warrant exercise unless a registration
statement under the Securities Act with respect to the shares of Common Stock underlying the Public Warrants is then effective
and a prospectus relating thereto is current, subject to the Company’s satisfying its obligations under Section 7.4.
No Warrant shall be exercisable and the Company shall not be obligated to issue shares of Common Stock upon exercise of a Warrant
unless the Common Stock issuable upon such Warrant exercise has been registered, qualified or deemed to be exempt from registration
or qualification under the securities laws of the state of residence of the Registered Holder of the Warrants. In the event that
the conditions in the two immediately preceding sentences are not satisfied with respect to a Warrant, the holder of such Warrant
shall not be entitled to exercise such Warrant and such Warrant may have no value and expire worthless, in which case the purchaser
of a Unit containing such Public Warrants shall have paid the full purchase price for the Unit solely for the shares of Common
Stock underlying such Unit. In no event will the Company be required to net cash settle the Warrant exercise. The Company may
require holders of Public Warrants to settle the Warrant on a “cashless basis” pursuant to Section 7.4.
If, by reason of any exercise of Warrants on a “cashless basis”, the holder of any Warrant would be entitled, upon
the exercise of such Warrant, to receive a fractional interest in a share of Common Stock, the Company shall round down to the
nearest whole number, the number of shares of Common Stock to be issued to such holder.

 

    5

     

    

 

3.3.4
Valid Issuance. All Common Stock issued upon the proper exercise of a Warrant in conformity with this Agreement shall be
validly issued, fully paid and non-assessable.

 

3.3.5
Date of Issuance. Each person in whose name any book-entry position or certificate, as applicable, for shares of Common
Stock is issued shall for all purposes be deemed to have become the holder of record of such shares of Common Stock on the date
on which the Warrant, or book-entry position representing such Warrant, was surrendered and payment of the Warrant Price was made,
irrespective of the date of delivery of such certificate in the case of a certificated Warrant, except that, if the date of such
surrender and payment is a date when the share transfer books of the Company or book-entry system of the Warrant Agent are closed,
such person shall be deemed to have become the holder of such shares of Common Stock at the close of business on the next succeeding
date on which the share transfer books or book-entry system are open.

 

3.3.6
Maximum Percentage. A holder of a Warrant may notify the Company in writing in the event it elects to be subject to the
provisions contained in this subsection 3.3.6; however, no holder of a Warrant shall be subject to this subsection 3.3.6 unless
he, she or it makes such election. If the election is made by a holder, the Warrant Agent shall not effect the exercise of the
holder’s Warrant, and such holder shall not have the right to exercise such Warrant, to the extent that after giving effect
to such exercise, such person (together with such person’s affiliates), to the Warrant Agent’s actual knowledge, would
beneficially own in excess of 4.8% or 9.8% (or such other amount as specified by the holder) (the “Maximum Percentage”)
of the shares of Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence,
the aggregate number of shares of Common Stock beneficially owned by such person and its affiliates shall include the number of
shares of Common Stock issuable upon exercise of the Warrant with respect to which the determination of such sentence is being
made, but shall exclude shares of Common Stock that would be issuable upon (x) exercise of the remaining, unexercised portion
of the Warrant beneficially owned by such person and its affiliates and (y) exercise or conversion of the unexercised or
unconverted portion of any other securities of the Company beneficially owned by such person and its affiliates (including, without
limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise
analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial
ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”). For purposes of the Warrant, in determining the number of outstanding
shares of Common Stock, the holder may rely on the number of outstanding shares of Common Stock as reflected in (1) the Company’s
most recent annual report on Form 10-K, quarterly report on Form 10-Q, current report on Form 8-K or other public
filing with the Commission as the case may be, (2) a more recent public announcement by the Company or (3) any other
notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. For any reason at
any time, upon the written request of the holder of the Warrant, the Company shall, within two (2) Business Days, confirm
orally and in writing to such holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding
shares of Common Stock shall be determined after giving effect to the conversion or exercise of equity securities of the Company
by the holder and its affiliates since the date as of which such number of outstanding shares of Common Stock was reported. By
written notice to the Company, the holder of a Warrant may from time to time increase or decrease the Maximum Percentage applicable
to such holder to any other percentage specified in such notice; provided, however, that any such increase shall not
be effective until the sixty-first (61st) day after such notice is delivered to the Company.

 

    6

     

    

 

4.
Adjustments.

 

4.1
Stock Dividends.

 

4.1.1
Split-Ups. If after the date hereof, and subject to the provisions of Section 4.6 below, the number of outstanding
shares of Common Stock is increased by a stock dividend payable in Common Stock, or by a split-up of the Common Stock or other
similar event, then, on the effective date of such stock dividend, split-up or similar event, the number of shares of Common Stock
issuable on exercise of each Warrant shall be increased in proportion to such increase in the outstanding shares of Common Stock.
A rights offering to holders of the Common Stock entitling holders to purchase Common Stock at a price less than the “Fair
Market Value” (as defined below) shall be deemed a stock dividend of a number of shares of Common Stock equal to the product
of (i) the number of shares of Common Stock actually sold in such rights offering (or issuable under any other equity securities
sold in such rights offering that are convertible into or exercisable for the Common Stock) multiplied by (ii) one (1) minus
the quotient of (x) the price per share of Common Stock paid in such rights offering divided by (y) the Fair Market Value.
For purposes of this subsection 4.1.1, (i) if the rights offering is for securities convertible into or exercisable for Common
Stock, in the determination of the price payable for Common Stock shall take into account any consideration received for such
rights, as well as any additional amount payable upon exercise or conversion and (ii) “Fair Market Value” means, for
purposes of this subsection 4.1.1 only, the volume weighted average price of the Common Stock as reported during the ten (10) trading
day period ending on the trading day prior to the first date on which the Common Stock trades on the applicable exchange or in
the applicable market, regular way, without the right to receive such rights.

 

4.1.2
Extraordinary Dividends. If the Company, at any time while the Warrants are outstanding and unexpired, shall pay a dividend
or make a distribution in cash, securities or other assets to the holders of the shares of Common Stock on account of such shares
of Common Stock (or other shares of the Company’s capital stock into which the Warrants are convertible), other than (a)
as described in subsection 4.1.1 above, (b) Ordinary Cash Dividends (as defined below), (c) to satisfy the redemption rights of
the holders of the shares of Common Stock in connection with a proposed initial Business Combination, (d) to satisfy the redemption
rights of the holders of the shares of Common Stock in connection with a stockholder vote to amend the Company’s amended
and restated certificate of incorporation to modify the substance or timing of the Company’s obligation to redeem 100% of
the public shares of Common Stock if the Company does not complete the Business Combination within the period set forth in the
Company’s amended and restated certificate of incorporation, or (e) in connection with the redemption of public shares upon
the failure of the Company to complete its initial Business Combination and any subsequent distribution of its assets upon its
liquidation (any such non-excluded event being referred to herein as an “Extraordinary Dividend”), then
the Warrant Price shall be decreased, effective immediately after the effective date of such Extraordinary Dividend, by the amount
of cash and/or the fair market value (as determined by the Board, in good faith) of any securities or other assets paid on each
share of Common Stock in respect of such Extraordinary Dividend. For purposes of this subsection 4.1.2, “Ordinary
Cash Dividends” means any cash dividend or cash distribution which, when combined on a per share basis, with the
per share amounts of all other cash dividends and cash distributions paid on the shares of Common Stock during the 365-day period
ending on the date of declaration of such dividend or distribution (as adjusted to appropriately reflect any of the events referred
to in other subsections of this Section 4 and excluding cash dividends or cash distributions that resulted in an adjustment to
the Warrant Price or to the number of shares of Common Stock issuable on exercise of each Warrant) does not exceed $0.50 (being
5% of the offering price of the Units in the Offering).

 

4.2
Aggregation of Shares. If after the date hereof, and subject to the provisions of Section 4.6 hereof, the
number of outstanding shares of Common Stock is decreased by a consolidation, combination, reverse stock split or reclassification
of shares of Common Stock or other similar event, then, on the effective date of such consolidation, combination, reverse stock
split, reclassification or similar event, the number of shares of Common Stock issuable on exercise of each Warrant shall be decreased
in proportion to such decrease in outstanding shares of Common Stock.

 

    7

     

    

 

4.3
Adjustments in Exercise Price.

 

4.3.1
Whenever the number of shares of Common Stock issuable upon the exercise of the Warrants is adjusted, as provided in
subsection 4.1.1 or 4.2 above, the Warrant Price shall be adjusted (to the nearest cent) by multiplying such Warrant Price
immediately prior to such adjustment by a fraction (x) the numerator of which shall be the number of shares of Common
Stock issuable upon the exercise of the Warrants immediately prior to such adjustment, and (y) the denominator of which
shall be the number of shares of Common Stock so issuable immediately thereafter.

 

4.3.2
If (i) the Company issues additional shares of Common Stock or securities convertible into or exercisable or exchangeable for
shares of Common Stock for capital raising purposes in connection with the closing of its initial Business Combination at an
issue price or effective issue price of less than $9.20 per share of Common Stock, with such issue price or effective issue
price to be determined in good faith by the Board (and in the case of any such issuance to the Sponsor or its affiliates,
without taking into account any founder shares held by such holder or affiliates, as applicable, prior to such issuance) (the
“New Issuance Price”), (ii) the aggregate gross proceeds from such issuances represent more than
50% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the
date of the consummation thereof (net of redemptions) and (iii) the volume weighted average trading price of the Common Stock
during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the initial
Business Combination (such price, the "Market Value") is below $9.20 per share, the Warrant Price
shall be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the New Issuance Price and
the Redemption Trigger Price (as defined below) shall be adjusted (to the nearest cent) to be equal to 180% of the higher of
the Market Value and the New Issuance Price.

 

4.4
Replacement of Securities upon Reorganization, etc. In the event of (a) any reclassification or reorganization of the outstanding
Common Stock (other than a change under subsections 4.1.1 or 4.1.2 or Section 4.2 hereof or that solely affects the par value
of the Common Stock), (b) any merger or consolidation of the Company with or into another entity or conversion of the Company
into another type of entity (other than a consolidation or merger in which the Company is the continuing corporation and that
does not result in any reclassification or reorganization of the outstanding Common Stock) or (c) the sale or conveyance of all
or substantially all of the Company’s assets in one transaction or a series of related transactions, the holders of Whole
Warrants shall thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in
the Warrants and in lieu of the Common Stock of the Company immediately theretofore purchasable and receivable upon the exercise
of the rights represented thereby, the kind and amount of shares of stock or other securities or property (including cash) receivable
upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer,
that the holder of the Warrants would have received if such holder had exercised his, her or its Whole Warrant(s) immediately
prior to such event (the “Alternative Issuance”); provided, however, that (i) if the holders of
the Common Stock were entitled to exercise a right of election as to the kind or amount of securities, cash or other assets receivable
upon such consolidation or merger, then the kind and amount of securities, cash or other assets constituting the Alternative Issuance
for which each Whole Warrant shall become exercisable shall be deemed to be the weighted average of the kind and amount received
per share by the holders of the Common Stock in such consolidation or merger that affirmatively make such election, and (ii) if
a tender, exchange or redemption offer shall have been made to, and accepted by, the holders of the Common Stock (other than a
tender, exchange or redemption offer made by the Company in connection with redemption rights held by stockholders of the Company
as provided for in the Company’s amended and restated certificate of incorporation or as a result of the repurchase of Common
Stock by the Company if a proposed initial Business Combination is presented to the stockholders of the Company for approval)
under circumstances in which, upon completion of such tender or exchange offer, the maker thereof, together with members of any
group (within the meaning of Rule 13d-5(b)(1) under the Exchange Act) of which such maker is a part, and together with any
affiliate or associate of such maker (within the meaning of Rule 12b-2 under the Exchange Act) and any members of any such
group of which any such affiliate or associate is a part, own beneficially (within the meaning of Rule 13d-3 under the Exchange
Act) more than 50% of the outstanding Common Stock, the holder of a Warrant shall be entitled to receive as the Alternative Issuance,
the highest amount of cash, securities or other property to which such holder would actually have been entitled as a stockholder
if such Warrant holder had exercised the Warrant prior to the expiration of such tender or exchange offer, accepted such offer
and all of the Common Stock held by such holder had been purchased pursuant to such tender or exchange offer, subject to adjustments
(from and after the consummation of such tender or exchange offer) as nearly equivalent as possible to the adjustments provided
for in this  Section 4; provided further, however, that if less than 70% of the consideration receivable by the
holders of the Common Stock in the applicable event is payable in the form of common stock in the successor entity that is listed
for trading on a national securities exchange or is quoted in an established over-the-counter market, or is to be so listed for
trading or quoted immediately following such event, and if the Registered Holder properly exercises the Warrant within thirty
(30) days following the public disclosure of the consummation of such applicable event by the Company pursuant to a Current Report
on Form 8-K filed with the Commission, the Warrant Price shall be reduced by an amount (in dollars) equal to the difference of
(i) the Warrant Price in effect prior to such reduction minus (ii) (A) the Per Share Consideration (as defined below) (but in
no event less than zero) minus (B) the Black-Scholes Warrant Value (as defined below). The “Black-Scholes Warrant
Value” means the value of a Warrant immediately prior to the consummation of the applicable event based on the Black-Scholes
Warrant Model for a Capped American Call on Bloomberg Financial Markets (“Bloomberg”). For purposes
of calculating such amount, (1) Section 6 of this Agreement shall be taken into account, (2) the price of each share
of Common Stock shall be the volume weighted average price of the Common Stock as reported during the ten (10) trading day period
ending on the trading day prior to the effective date of the applicable event, (3) the assumed volatility shall be the 90 day
volatility obtained from the HVT function on Bloomberg determined as of the trading day immediately prior to the day of the announcement
of the applicable event, and (4) the assumed risk-free interest rate shall correspond to the U.S. Treasury rate for a period equal
to the remaining term of the Warrant. “Per Share Consideration” means (i) if the consideration
paid to holders of the Common Stock consists exclusively of cash, the amount of such cash per share of Common Stock, and (ii)
in all other cases, the volume weighted average price of the Common Stock as reported during the ten (10) trading day period ending
on the trading day prior to the effective date of the applicable event. If any reclassification or reorganization also results
in a change in shares of Common Stock covered by subsection 4.1.1, then such adjustment shall be made pursuant to subsection
4.1.1 or Sections 4.2, 4.3 and this Section 4.4. The provisions of this Section 4.4 shall similarly
apply to successive reclassifications, reorganizations, mergers or consolidations, sales or other transfers. In no event will
the Warrant Price be reduced to less than the par value per share issuable upon exercise of the Warrant.

 

    8

     

    

 

4.5
Notices of Changes in Warrant. Upon every adjustment of the Warrant Price or the number of shares issuable upon exercise
of a Warrant, the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Warrant Price resulting
from such adjustment and the increase or decrease, if any, in the number of shares purchasable at such price upon the exercise
of a Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based.
Upon the occurrence of any event specified in Sections 4.1, 4.2, 4.3 or 4.4, the Company shall give written notice of the occurrence
of such event to each holder of a Warrant, at the last address set forth for such holder in the Warrant Register, of the record
date or the effective date of the event. Failure to give such notice, or any defect therein, shall not affect the legality or
validity of such event.

 

4.6
No Fractional Shares. Notwithstanding any provision contained in this Agreement to the contrary, the Company shall not
issue fractional shares upon exercise of Warrants. If, by reason of any adjustment made pursuant to this Section 4, the holder
of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share, the Company
shall, upon such exercise, round down to the nearest whole number, the number of the shares of Common Stock to be issued to such
holder.

 

4.7
Form of Warrant. The form of Warrant need not be changed because of any adjustment pursuant to this  Section 4,
and Warrants issued after such adjustment may state the same Warrant Price and the same number of shares as is stated in the Warrants
initially issued pursuant to this Agreement; provided, however, that the Company may at any time in its sole discretion make any
change in the form of Warrant that the Company may deem appropriate and that does not affect the substance thereof, and any Warrant
thereafter issued or countersigned, whether in exchange or substitution for an outstanding Warrant or otherwise, may be in the
form as so changed.

 

4.8
Other Events. In case any event shall occur affecting the Company as to which none of the provisions of preceding subsections
of this Section 4 are strictly applicable, but which would require an adjustment to the terms of the Warrants in order to
(i) avoid an adverse impact on the Warrants and (ii) effectuate the intent and purpose of this Section 4, then,
in each such case, the Company shall appoint a firm of independent public accountants, or an investment banking or other appraisal
firm of recognized national standing, which shall give its opinion as to whether or not any adjustment to the rights represented
by the Warrants is necessary to effectuate the intent and purpose of this Section 4 and, if they determine that an adjustment
is necessary, the terms of such adjustment; provided, however, that under no circumstances shall the Warrants be adjusted pursuant
to this Section 4.8 (a) as a result of any issuance of securities in connection with a Business Combination or (b) solely as a
result of an adjustment to the conversion ratio of the Company’s Class B common stock, $0.0001 par value per share, into
Common Stock. The Company shall adjust the terms of the Warrants in a manner that is consistent with any adjustment recommended
in such opinion.

 

    9

     

    

 

5.
Transfer and Exchange of Warrants.

 

5.1
Registration of Transfer. The Warrant Agent shall register the transfer, from time to time, of any outstanding Warrant
upon the Warrant Register, upon surrender of such Warrant for transfer, in the case of certificated Warrants, properly endorsed
with signatures properly guaranteed and accompanied by appropriate instructions for transfer. Upon any such transfer, a new Warrant
representing an equal aggregate number of Warrants shall be issued and the old Warrant shall be cancelled by the Warrant Agent.
In the case of certificated Warrants, the Warrants so cancelled shall be delivered by the Warrant Agent to the Company from time
to time upon request.

 

5.2
Procedure for Surrender of Warrants. Whole may be surrendered to the Warrant Agent, together with a written request for
exchange or transfer, and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested by
the Registered Holder of the Warrants so surrendered, representing an equal aggregate number of Warrants; provided, however,
that except as otherwise provided herein or in any Book-Entry Warrant Certificate or Definitive Warrant Certificate, each Book-Entry
Warrant Certificate and Definitive Warrant Certificate may be transferred only in whole and only to the Depositary, to another
nominee of the Depositary, to a successor depository, or to a nominee of a successor depository; provided further, however,
that in the event that a Warrant surrendered for transfer bears a restrictive legend (as in the case of the Placement Warrants
and the Working Capital Warrants), the Warrant Agent shall not cancel such Warrant and issue new Warrants in exchange thereof
until the Warrant Agent has received an opinion of counsel for the Company stating that such transfer may be made and indicating
whether the new Warrants must also bear a restrictive legend.

 

5.3
Fractional Warrants. The Warrant Agent shall not be required to effect any registration of transfer or exchange which shall
result in the issuance of a warrant certificate or book-entry certificate for a fraction of a warrant, except as part of the Units.

 

5.4
Service Charges. No service charge shall be made for any exchange or registration of transfer of Warrants.

 

5.5
Warrant Execution and Countersignature. The Warrant Agent is hereby authorized to countersign and to deliver, in accordance
with the terms of this Agreement, the Warrants required to be issued pursuant to the provisions of this Section 5, and the
Company, whenever required by the Warrant Agent, shall supply the Warrant Agent with Warrants duly executed on behalf of the Company
for such purpose.

 

5.6
Transfer of Warrants. Prior to the Detachment Date, the Public Warrants may be transferred or exchanged only together with
the Unit in which such Warrant is included, and only for the purpose of effecting, or in conjunction with, a transfer or exchange
of such Unit. Furthermore, each transfer of a Unit on the register relating to such Units shall operate also to transfer the Warrants
included in such Unit. Notwithstanding the foregoing, the provisions of this Section 5.6 shall have no effect on
any transfer of Warrants on and after the Detachment Date.

 

    10

     

    

 

6.
Redemption.

 

6.1
Redemption. Subject to Section 6.4 hereof, not less than all of the outstanding Warrants may be redeemed at the option
of the Company, at any time while they are exercisable and prior to their expiration, at the office of the Warrant Agent, upon
notice to the Registered Holders of the Warrants, as described in Section 6.2 below, at a price of $0.01 per Warrant (the
“Redemption Price”); provided, that the last sales price of the Common Stock (or the closing bid price
of the Common Stock if shares of the Common Stock are not traded on any specific trading day) reported has been at least $18.00
per share (subject to adjustment in compliance with Section 4 hereof) (the “Redemption Trigger Price”),
on each of twenty (20) trading days within the thirty (30) trading-day period ending on the third Business Day prior
to the date on which notice of the redemption is given; and, provided further that there is an effective registration statement
covering the Common Stock issuable upon exercise of the Warrants, and a current prospectus relating thereto, available throughout
the 30-day Redemption Period (as defined in Section 6.2 below) or the Company has elected to require the exercise of the
Warrants on a “cashless basis” pursuant to subsection 3.3.1.; and provided further that, after aggregating all of
the fractional Warrants held by a Registered Holder, there remains a fractional Warrant held by such Registered Holder, such fractional
Warrant shall not be redeemed and will terminate on the Redemption Date (as defined in Section 6.2).

 

6.2
Date Fixed for, and Notice of, Redemption. If the Company elects to redeem the Warrants in accordance with Section 6.1,
the Company shall fix a date for the redemption (the “Redemption Date”). Notice of redemption shall
be mailed by first class mail, postage prepaid, by the Company not less than thirty (30) days prior to the Redemption Date
(such 30-day period, the “Redemption Period”) to the Registered Holders of the Warrants to be redeemed
at their last addresses as they shall appear on the registration books. Any notice mailed in the manner herein provided shall
be conclusively presumed to have been duly given whether or not the Registered Holder received such notice.

 

6.3
Exercises After Notice of Redemption. The Warrants may be exercised for cash (or on a “cashless basis” in accordance
with subsection 3.3.1(b)) at any time after notice of redemption shall have been given by the Company pursuant to Section 6.2
hereof and prior to the Redemption Date. If the Company determines to require all holders of Warrants to exercise their Warrants
on a “cashless basis” pursuant to subsection 3.3.1, the notice of redemption shall contain the information necessary
to calculate the number of shares of Common Stock to be received upon exercise of the Warrants, including the “Fair Market
Value” (as such term is defined in subsection 3.3.1(b)) in such case. On and after the Redemption Date, the record holder
of the Warrants shall have no further rights except to receive, upon surrender of the Warrants, the Redemption Price.

 

6.4
Exclusion of Placement Warrants and Working Capital Warrants. The Company agrees that the redemption rights provided in
this Section 6 shall not apply to the Placement Warrants or the Working Capital Warrants if at the time of the
redemption such Placement Warrants or Working Capital Warrants continue to be held by the Sponsor, Cantor or any Permitted Transferees,
as applicable. However, once such Placement Warrants or Working Capital Warrants are transferred (other than to Permitted
Transferees under Section 2.5), the Company may redeem the Placement Warrants and the Working Capital Warrants, provided
that the criteria for redemption are met, including the opportunity of the holder of such Placement Warrants or Working Capital
Warrants to exercise the Placement Warrants and the Working Capital Warrants prior to redemption pursuant to Section
6.3. Placement Warrants and Working Capital Warrants that are transferred to persons other than Permitted Transferees shall upon
such transfer cease to be Placement Warrants or Working Capital Warrants and shall become Public Warrants under this Agreement.

 

7.
Other Provisions Relating to Rights of Holders of Warrants.

 

7.1
No Rights as Stockholder. A Warrant does not entitle the Registered Holder thereof to any of the rights of a stockholder
of the Company, including, without limitation, the right to receive dividends or other distributions, exercise any preemptive
rights to vote or to consent or to receive notice as stockholders in respect of the meetings of stockholders or the election of
directors of the Company or any other matter.

 

7.2
Lost, Stolen, Mutilated, or Destroyed Warrants. If any Warrant is lost, stolen, mutilated, or destroyed, the Company and
the Warrant Agent may on such terms as to indemnity or otherwise as they may in their discretion impose (which shall, in the case
of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor, and date as the Warrant
so lost, stolen, mutilated, or destroyed. Any such new Warrant shall constitute a substitute contractual obligation of the Company,
whether or not the allegedly lost, stolen, mutilated, or destroyed Warrant shall be at any time enforceable by anyone.

 

    11

     

    

 

7.3
Reservation of Common Stock. The Company shall at all times reserve and keep available a number of shares of its authorized
but unissued Common Stock that shall be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant
to this Agreement.

 

7.4
Registration of Common Stock; Cashless Exercise at Company’s Option.

 

7.4.1
Registration of Common Stock. The Company agrees that as soon as practicable, but in no event later than fifteen (15) Business
Days after the closing of its initial Business Combination, it shall use its best efforts to file with the Commission a post-effective
amendment to the Registration Statement, or a new registration statement, for the registration, under the Securities Act, of the
Common Stock issuable upon exercise of the Warrants, and it shall use its best efforts to take such action as is necessary to
register or qualify for sale, in those states in which the Warrants were initially offered by the Company, the Common Stock issuable
upon exercise of the Warrants, to the extent an exemption is not available. The Company shall use its best efforts to cause the
same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto,
until the expiration of the Warrants in accordance with the provisions of this Agreement. If any such post-effective amendment
or registration statement has not been declared effective by the sixtieth (60th) Business Day following the closing of the Business
Combination, holders of the Warrants shall have the right, during the period beginning on the sixty-first (61st) Business Day
after the closing of the Business Combination and ending upon such post-effective amendment or registration statement being declared
effective by the Commission, and during any other period when the Company shall fail to have maintained an effective registration
statement covering the Common Stock issuable upon exercise of the Warrants, to exercise Whole Warrants on a “cashless basis,”
by exchanging Whole Warrants (in accordance with Section 3(a)(9) of the Securities Act or another exemption) for that number
of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number of shares of Common Stock
underlying the Whole Warrants, multiplied by the difference between the Warrant Price and the “Fair Market Value”
(as defined below) by (y) the Fair Market Value. Solely for purposes of this Section 7.4, “Fair Market
Value” shall mean the volume weighted average price of the Common Stock as reported during the ten (10) trading day
period ending on the trading day prior to the date that notice of exercise is received by the Warrant Agent from the holder of
such Whole Warrants or its securities broker or intermediary. The date that notice of cashless exercise is received by the Warrant
Agent shall be conclusively determined by the Warrant Agent. In connection with the “cashless exercise” of a Public
Warrant, the Company shall, upon request, provide the Warrant Agent with an opinion of counsel for the Company (which shall be
an outside law firm with securities law experience) stating that (i) the exercise of Whole Warrants on a cashless basis in
accordance with this Section 7.4 is not required to be registered under the Securities Act and (ii) the Common Stock
issued upon such exercise shall be freely tradable under United States federal securities laws by anyone who is not an affiliate
(as such term is defined in Rule 144 under the Securities Act) of the Company and, accordingly, shall not be required to
bear a restrictive legend. For the avoidance of any doubt, unless and until all Whole Warrants have been exercised, the Company
shall continue to be obligated to comply with its registration obligations under the first three sentences of this Section 7.4.1.

 

7.4.2
Cashless Exercise at Company’s Option. If the Common Stock is at the time of any exercise of a Whole Warrant not
listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section
18(b)(1) of the Securities Act, the Company may, at its option, (i) require holders of Public Warrants who exercise Public Warrants
(which, for the avoidance of doubt may only be Whole Warrants) to exercise such Public Warrants on a “cashless basis”
in accordance with Section 3(a)(9) of the Securities Act as described in subsection 7.4.1 and (ii) in the event the Company so
elects, the Company shall not be required to file or maintain in effect a registration statement for the registration, under the
Securities Act, of the Common Stock issuable upon exercise of the Warrants, notwithstanding anything in this Agreement to the
contrary. If the Company does not elect at the time of exercise to require a holder of Public Warrants who exercises Public Warrants
to exercise such Public Warrants on a “cashless basis,” it agrees to use its best efforts to register or qualify for
sale the Common Stock issuable upon exercise of the Public Warrant under the blue sky laws of the state of residence (in those
states in which the Warrants were initially offered by the Company) of the exercising Public Warrant holder to the extent an exemption
is not available

 

    12

     

    

 

8.
Concerning the Warrant Agent and Other Matters.

 

8.1
Payment of Taxes. The Company shall from time to time promptly pay all taxes and charges that may be imposed upon the Company
or the Warrant Agent in respect of the issuance or delivery of Common Stock upon the exercise of the Warrants, but the Company
shall not be obligated to pay any transfer taxes in respect of the Warrants or such shares.

 

8.2
Resignation, Consolidation, or Merger of Warrant Agent.

 

8.2.1
Appointment of Successor Warrant Agent. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties
and be discharged from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing
to the Company. If the office of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company
shall appoint in writing a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment
within a period of thirty (30) days after it has been notified in writing of such resignation or incapacity by the Warrant
Agent or by the holder of a Warrant (who shall, with such notice, submit his Warrant for inspection by the Company), then the
holder of any Warrant may apply to the Supreme Court of the State of New York for the County of New York for the appointment of
a successor Warrant Agent at the Company’s cost. Any successor Warrant Agent, whether appointed by the Company or by such
court, shall be a corporation organized and existing under the laws of the State of New York, in good standing and having its
principal office in the Borough of Manhattan, City and State of New York, and authorized under such laws to exercise corporate
trust powers and subject to supervision or examination by federal or state authority. After appointment, any successor Warrant
Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations of its predecessor Warrant Agent
with like effect as if originally named as Warrant Agent hereunder, without any further act or deed; but if for any reason it
becomes necessary or appropriate, the predecessor Warrant Agent shall execute and deliver, at the expense of the Company, an instrument
transferring to such successor Warrant Agent all the authority, powers, and rights of such predecessor Warrant Agent hereunder;
and upon request of any successor Warrant Agent the Company shall make, execute, acknowledge, and deliver any and all instruments
in writing for more fully and effectually vesting in and confirming to such successor Warrant Agent all such authority, powers,
rights, immunities, duties, and obligations.

 

8.2.2
Notice of Successor Warrant Agent. In the event a successor Warrant Agent shall be appointed, the Company shall give notice
thereof to the predecessor Warrant Agent and the Transfer Agent for the Common Stock not later than the effective date of any
such appointment.

 

8.2.3
Merger or Consolidation of Warrant Agent. Any corporation into which the Warrant Agent may be merged or with which it may
be consolidated or any corporation resulting from any merger or consolidation to which the Warrant Agent shall be a party shall
be the successor Warrant Agent under this Agreement without any further act.

 

8.3
Fees and Expenses of Warrant Agent.

 

8.3.1
Remuneration. The Company agrees to pay the Warrant Agent reasonable remuneration for its services as such Warrant Agent
hereunder and shall, pursuant to its obligations under this Agreement, reimburse the Warrant Agent upon demand for all expenditures
that the Warrant Agent may reasonably incur in the execution of its duties hereunder.

 

8.3.2
Further Assurances. The Company agrees to perform, execute, acknowledge, and deliver or cause to be performed, executed,
acknowledged, and delivered all such further and other acts, instruments, and assurances as may reasonably be required by the
Warrant Agent for the carrying out or performing of the provisions of this Agreement.

 

    13

     

    

 

8.4
Liability of Warrant Agent.

 

8.4.1
Reliance on Company Statement. Whenever in the performance of its duties under this Agreement, the Warrant Agent shall
deem it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any
action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed
to be conclusively proved and established by a statement signed by the President, Chief Executive Officer or Chairman of the Board
of the Company and delivered to the Warrant Agent. The Warrant Agent may rely upon such statement for any action taken or suffered
in good faith by it pursuant to the provisions of this Agreement.

 

8.4.2
Indemnity. The Warrant Agent shall be liable hereunder only for its own gross negligence, willful misconduct or bad faith.
The Company agrees to indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, costs
and reasonable counsel fees, for anything done or omitted by the Warrant Agent in the execution of this Agreement, except as a
result of the Warrant Agent’s gross negligence, willful misconduct or bad faith.

 

8.4.3
Exclusions. The Warrant Agent shall have no responsibility with respect to the validity of this Agreement or with respect
to the validity or execution of any Warrant (except its countersignature thereof). The Warrant Agent shall not be responsible
for any breach by the Company of any covenant or condition contained in this Agreement or in any Warrant. The Warrant Agent shall
not be responsible to make any adjustments required under the provisions of Section 4 hereof or responsible for the manner,
method, or amount of any such adjustment or the ascertaining of the existence of facts that would require any such adjustment;
nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any
Common Stock to be issued pursuant to this Agreement or any Warrant or as to whether any Common Stock shall, when issued, be valid
and fully paid and non-assessable.

 

8.5
Acceptance of Agency. The Warrant Agent hereby accepts the agency established by this Agreement and agrees to perform the
same upon the terms and conditions herein set forth and among other things, shall account promptly to the Company with respect
to Warrants exercised and concurrently account for, and pay to the Company, all monies received by the Warrant Agent for the purchase
of the Common Stock through the exercise of the Warrants.

 

8.6
Waiver. The Warrant Agent has no right of set-off or any other right, title, interest or claim of any kind (“Claim”)
in, or to any distribution of, the Trust Account (as defined in that certain Investment Management Trust Agreement, dated as of
the date hereof, by and between the Company and the Warrant Agent as trustee thereunder) and hereby agrees not to seek recourse,
reimbursement, payment or satisfaction for any Claim against the Trust Account for any reason whatsoever. The Warrant Agent hereby
waives any and all Claims against the Trust Account and any and all rights to seek access to the Trust Account.

 

9.
Miscellaneous Provisions.

 

9.1
Successors. All the covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent
shall bind and inure to the benefit of their respective successors and assigns.

 

9.2
Notices. Any notice, statement or demand authorized by this Agreement shall be sufficiently given (i) when so delivered
if by hand or overnight delivery, (ii) upon receipt of by the intended recipient if by email or facsimile, or (ii) if sent by
certified mail or private courier service within five (5) days after deposit of such notice, postage prepaid, addressed (until
another address is filed in writing with the Warrant Agent) as follows:

 

If
to the Company:

 

FinTech
Acquisition Corp. IV

2929
Arch Street, Suite 1703

Philadelphia,
PA 19104-2870

Attention:
James J. McEntee, President

 

    14

     

    

 

If
to the Warrant Agent:

 

Continental
Stock Transfer & Trust Company

One
State Street, 30th Floor

New
York, New York 10004

Fax:
212-616-7615

Attention:
Compliance Department

 

with
a copy in each case (which shall not constitute service) to:

 

Ledgewood,
PC

2001
Market Street, Suite 3400

Philadelphia
PA 19103

Fax:
215-735-2513

Attention:  Mark
Rosenstein, Esq.

 

9.3
Applicable Law. The validity, interpretation, and performance of this Agreement and of the Warrants shall be governed in
all respects by the laws of the State of New York and without giving effect to conflicts of law principles that would result in
the application of the substantive laws of another jurisdiction.

 

9.4
Persons Having Rights under this Agreement. Nothing in this Agreement shall be construed to confer upon, or give to, any
person or corporation other than the parties hereto and the Registered Holders of the Warrants any right, remedy, or claim under
or by reason of this Agreement or of any covenant, condition, stipulation, promise, or agreement hereof. All covenants, conditions,
stipulations, promises, and agreements contained in this Agreement shall be for the sole and exclusive benefit of the parties
hereto and their successors and assigns and of the Registered Holders of the Warrants.

 

9.5
Examination of the Agreement. A copy of this Agreement shall be available at all reasonable times at the office of the
Warrant Agent in the Borough of Manhattan, City and State of New York, for inspection by the Registered Holder of any Warrant.
The Warrant Agent may require any such holder to submit his Warrant for inspection by it.

 

9.6
Counterparts. This Agreement may be executed in any number of counterparts and each of such counterparts shall for all
purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. Delivery
of a signed counterpart of this Agreement by facsimile or electronic transmission shall constitute valid and sufficient delivery
thereof.

 

9.7
Effect of Headings. The section headings herein are for convenience only and are not part of this Agreement and shall not
affect the interpretation thereof.

 

9.8
Amendments. This Agreement may be amended by the parties hereto without the consent of any Registered Holder for the purpose
of curing any ambiguity, or curing, correcting or supplementing any defective provision contained herein or adding or changing
any other provisions with respect to matters or questions arising under this Agreement as the parties may deem necessary or desirable
and that the parties deem shall not adversely affect the interest of the Registered Holders. All other modifications or amendments,
including any amendment to increase the Warrant Price or shorten the Exercise Period and any amendment to the terms of only the
Placement Warrants or Working Capital Warrants, shall require the vote or written consent of the Registered Holders of 65% of
the then outstanding Public Warrants. Notwithstanding the foregoing, the Company may lower the Warrant Price or extend the duration
of the Exercise Period pursuant to Sections 3.1 and 3.2, respectively, without the consent of the Registered Holders.

 

9.9
Severability. This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision
hereof shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore,
in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part
of this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and
enforceable.

 

[Remainder
of page intentionally left blank. Signature page follows.]

 

    15

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written.

 

	 	FINTECH
    ACQUISITION CORP. IV  
	 	 
	 	By: 	/s/ James J. McEntee,
III
	 	 	Name:  	James J. McEntee, III
	 	 	Title: 	President and Secretary
	 	 	 	 
	 	CONTINENTAL
    STOCK TRANSFER & TRUST COMPANY,  
	 	as
    Warrant Agent 
	 	 
	 	By: 	/s/
Isaac J. Kagan
	 	 	Name: 	Isaac J. Kagan
	 	 	Title: 	Vice President

 

 

 

 

 

[FinTech
IV – Warrant Agreement]

 

    16

     

    

 

EXHIBIT
A

 

[Form
of Warrant Certificate]

 

[FACE]

 

Number

 

Warrants

 

THIS
WARRANT SHALL BE VOID IF NOT EXERCISED PRIOR TO

 THE
EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR

 IN
THE WARRANT AGREEMENT DESCRIBED BELOW

 

FINTECH
ACQUISITION CORP. IV

A
Delaware corporation

 

CUSIP
31810N 112

 

Warrant
Certificate

 

This
Warrant Certificate certifies that                       ,
or registered assigns, is the registered holder of              warrant(s)
(the “Warrants” and each, a “Warrant”) to purchase shares of Class A common
stock, $0.0001 par value (the “Common Stock”), of FinTech Acquisition Corp. IV (the “Company”).
Each Warrant entitles the holder, upon exercise during the period set forth in the Warrant Agreement referred to below, to receive
from the Company that number of fully paid and non-assessable shares of Common Stock (each, a “Warrant”)
as set forth below, at the exercise price (the “Exercise Price”) as determined pursuant to the Warrant
Agreement, payable in lawful money (or through “cashless exercise” as provided for in the Warrant Agreement)
of the United States of America upon surrender of this Warrant Certificate and payment of the Exercise Price at the office or
agency of the Warrant Agent referred to below, subject to the conditions set forth herein and in the Warrant Agreement. Defined
terms used in this Warrant Certificate but not defined herein shall have the meanings given to them in the Warrant Agreement (as
defined on the reverse hereof).

 

Each
Warrant is initially exercisable for one fully paid and non-assessable share of Common Stock; provided, however, that no fractional
Warrant may be exercised unless accompanies by other fractional Warrants that, in the aggregate, allow for the purchase of one
full share of Common Stock or an integral multiple thereof. The number of shares of Common Stock issuable upon exercise of the
Warrants is subject to adjustment upon the occurrence of certain events set forth in the Warrant Agreement. 

 

The
initial Exercise Price per share of Common Stock for any Warrant is equal to $11.50 per share. The Exercise Price is subject to
adjustment upon the occurrence of certain events set forth in the Warrant Agreement.

 

Subject
to the conditions set forth in the Warrant Agreement, the Warrants may be exercised only during the Exercise Period and to the
extent not exercised by the end of such Exercise Period, such Warrants shall become void.

 

Reference
is hereby made to the further provisions of this Warrant Certificate set forth on the reverse hereof and such further provisions
shall for all purposes have the same effect as though fully set forth at this place.

  

This
Warrant Certificate shall not be valid unless countersigned by the Warrant Agent, as such term is used in the Warrant Agreement.

 

    17

     

    

 

This
Warrant Certificate shall be governed by and construed in accordance with the internal laws of the State of New York, without
regard to conflicts of laws principles thereof.

 

	 	FINTECH
                                         ACQUISITION CORP. IV
	 	 
	 	By:	 
	 	 	Name: 	James J. McEntee, III 
	 	 	Title: 	President
	 	 	 
	 	CONTINENTAL STOCK TRANSFER &
    TRUST COMPANY,
	 	as Warrant Agent  
	 	 
	 	By:	         
	 	 	Name: 	 
	 	 	Title:  	 

 

    18

     

    

 

[Form
of Warrant Certificate]

 

[REVERSE]

 

The
Warrants evidenced by this Warrant Certificate are part of a duly authorized issue of Warrants entitling the holder on exercise
to receive shares of Common Stock and are issued or to be issued pursuant to a Warrant Agreement dated as of                               ,
2020 (the “Warrant Agreement”), duly executed and delivered by the Company to Continental Stock Transfer&
Trust Company, a New York limited purpose trust company, as warrant agent (the “Warrant Agent”),
which Warrant Agreement is hereby incorporated by reference in and made a part of this instrument and is hereby referred to for
a description of the rights, limitation of rights, obligations, duties and immunities thereunder of the Warrant Agent, the Company
and the holders (the words  “holders” or “holder” meaning
the Registered Holders or Registered Holder) of the Warrants. A copy of the Warrant Agreement may be obtained by the holder hereof
upon written request to the Company. Defined terms used in this Warrant Certificate but not defined herein shall have the meanings
given to them in the Warrant Agreement.

 

Subject
to the provisions of the Warrant Agreement with respect to fractional Warrants, Warrants may be exercised at any time during the
Exercise Period set forth in the Warrant Agreement. The holder of Warrants evidenced by this Warrant Certificate may exercise
them by surrendering this Warrant Certificate, with the form of election to purchase set forth hereon properly completed and executed,
together with payment of the Exercise Price as specified in the Warrant Agreement (or through “cashless exercise”
if permitted by the Warrant Agreement) at the principal corporate trust office of the Warrant Agent. In the event that upon any
exercise of Warrants evidenced hereby the number of Warrants exercised shall be less than the total number of Warrants evidenced
hereby, there shall be issued to the holder hereof or his, her or its assignee, a new Warrant Certificate evidencing the number
of Warrants not exercised.

 

Notwithstanding
anything else in this Warrant Certificate or the Warrant Agreement, no Warrant may be exercised unless at the time of exercise
(i) a registration statement covering the shares of Common Stock to be issued upon exercise is effective under the Securities
Act and (ii) a prospectus thereunder relating to the shares of Common Stock is current, except through “cashless
exercise” if permitted by the Warrant Agreement.  Additionally, if the Corporation fails to enter into
a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination, involving
the Corporation and one or more businesses by                      , 2022 (unless extended), the Warrants evidenced by this Warrant Certificate
shall expire worthless.

 

The
Warrant Agreement provides that, upon the occurrence of certain events, the number of the Warrants set forth on the face hereof
may, subject to certain conditions, be adjusted. If, upon exercise of a Warrant, the holder hereof would be entitled to receive
a fractional interest in a share of Common Stock, the Company shall, upon exercise, round down to the nearest whole number of
shares of Common Stock to be issued to the holder of the Warrant.

 

Warrant
Certificates, when surrendered at the principal corporate trust office of the Warrant Agent by the Registered Holder thereof in
person or by legal representative or attorney duly authorized in writing, may be exchanged, in the manner and subject to the limitations
provided in the Warrant Agreement, but without payment of any service charge, for another Warrant Certificate or Warrant Certificates
of like tenor evidencing in the aggregate a like number of Warrants.

 

Upon
due presentation for registration of transfer of this Warrant Certificate at the office of the Warrant Agent a new Warrant Certificate
or Warrant Certificates of like tenor and evidencing in the aggregate a like number of Warrants shall be issued to the transferee(s)
in exchange for this Warrant Certificate, subject to the limitations provided in the Warrant Agreement, without charge except
for any tax or other governmental charge imposed in connection therewith.

 

    19

     

    

 

The
Company and the Warrant Agent may deem and treat the Registered Holder(s) thereof as the absolute owner(s) of this Warrant Certificate
(notwithstanding any notation of ownership or other writing hereon made by anyone), for the purpose of any exercise hereof, of
any distribution to the holder(s) hereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected
by any notice to the contrary. Neither the Warrants nor this Warrant Certificate entitles any holder hereof to any rights of a
stockholder of the Company.

 

Election
to Purchase

 

(To
Be Executed Upon Exercise of Warrant)

 

The
undersigned hereby irrevocably elects to exercise the right, represented by this Warrant Certificate, to receive                        shares
of Common Stock and herewith tenders payment for such shares to the order of FinTech Acquisition Corp. IV (the “Company”)
in the amount of $                    
  in accordance with the terms hereof. The undersigned requests that a certificate for such shares be registered in
the name of                     
, whose address is                        and
that such shares be delivered to                        whose
address is                      
.. If said number of shares is less than all of the shares of Common Stock purchasable hereunder, the undersigned requests that
a new Warrant Certificate representing the remaining balance of such shares be registered in the name of                      
, whose address is                      
, and that such Warrant Certificate be delivered to                      
, whose address is                      
..

 

In
the event that the Warrant has been called for redemption by the Company pursuant to Section 6 of the Warrant Agreement and
the Company has required cashless exercise pursuant to Section 6.3 of the Warrant Agreement, the number of shares that this
Warrant is exercisable for shall be determined in accordance with subsection 3.3.1(b) and Section 6.3 of the Warrant Agreement.

 

In
the event that the Warrant is a Placement Warrant that is to be exercised on a “cashless basis”
pursuant to subsection 3.3.1(c) of the Warrant Agreement, the number of shares that this Warrant is exercisable for shall be determined
in accordance with subsection 3.3.1(c) of the Warrant Agreement.

 

In
the event that the Warrant is to be exercised on a “cashless basis” pursuant to Section
7.4 of the Warrant Agreement, the number of shares that this Warrant is exercisable for shall be determined in accordance with
Section 7.4 of the Warrant Agreement.

 

In
the event that the Warrant may be exercised, to the extent allowed by the Warrant Agreement, through cashless exercise (i) the
number of shares that this Warrant is exercisable for would be determined in accordance with the relevant section of the Warrant
Agreement which allows for such cashless exercise and (ii) the holder hereof shall complete the following sentence: The undersigned
hereby irrevocably elects to exercise the right, represented by this Warrant Certificate, through the cashless exercise provisions
of the Warrant Agreement, to receive shares of Common Stock. If said number of shares is less than all of the shares of Common
Stock purchasable hereunder (after giving effect to the cashless exercise), the undersigned requests that a new Warrant Certificate
representing the remaining balance of such shares be registered in the name of, whose address is, and that such Warrant Certificate
be delivered to, whose address is ________.

 

Date:                    ,
20

 

	 	(Signature)
	 	 
	 	(Address)
	 	 
	 	(Tax Identification Number)

 

Signature
Guaranteed:                                        

 

THE
SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND
CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15).

 

    20

     

    

 

LEGEND

 

THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
OR ANY STATE SECURITIES LAWS AND NEITHER THE SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR
OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR SUCH LAWS OR AN EXEMPTION
FROM REGISTRATION UNDER THE SECURITIES ACT AND SUCH LAWS WHICH, IN THE OPINION OF COUNSEL FOR THIS CORPORATION, IS AVAILABLE.

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER PURSUANT TO A LETTER AGREEMENT BETWEEN FINTECH
ACQUISITION CORP. IV, FINTECH INVESTOR HOLDINGS IV, LLC, FINTECH MASALA ADVISORS IV, LLC AND THE DIRECTORS, OFFICERS AND CERTAIN
STOCKHOLDERS OF FINTECH ACQUISITION CORP. IV AND MAY ONLY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF PURSUANT
TO THE TERMS SET FORTH THEREIN.

 

	No.                    	 	                    
    Warrants

 

 

21

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}]]